epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Depacon

valproate sodium

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Black Box Warnings .

Brand Discontinued in US

select or search generic name for alternatives

Adult Dosing .

Dosage forms:  --

Brand Discontinued in US

[see generic]

Peds Dosing .

Dosage forms:  --

Brand Discontinued in US

[see generic]

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@1f9cc10
  • Brand Discontinued in US

Drug Interactions .

Overview

valproic acid

GABA modulator

Interaction Characteristics:
  • UGT1A4 substrate
  • UGT1A9 substrate
  • UGT2B7 substrate
  • epoxide hydrolase inhibitor
  • UGT1A9 inhibitor
  • UGT2B7 inhibitor
  • UGT2B15 inhibitor
  • CYP1A2 inducer, weak
  • UGT1A1 inducer
  • affected by altered fat absorption
  • antiepileptic agent
  • antiplatelet effects
  • binds to anion exchange resin/polymer
  • CNS depression
  • hyperammonemia
  • myelosuppressive effects

Contraindicated

  • amifampridine
  • Depacon (valproate sodium)
    +
    amifampridine
    1 interaction

    Contraindicated

    valproic acid + amifampridine

    contraindicated if seizure disorder use; otherwise, caution advised: combo may alter seizure control (antagonistic effects, amifampridine may decr. seizure threshold)

  • bupropion
  • Depacon (valproate sodium)
    +
    bupropion
    1 interaction

    Contraindicated

    valproic acid + bupropion

    contraindicated if seizure disorder use; otherwise, consider lower bupropion doses: combo may alter seizure control (antagonistic effects, bupropion may decr. seizure threshold)

  • dalfampridine
  • Depacon (valproate sodium)
    +
    dalfampridine
    1 interaction

    Contraindicated

    valproic acid + dalfampridine

    contraindicated if seizure disorder use; otherwise, caution advised: combo may alter seizure control (antagonistic effects, dalfampridine may decr. seizure threshold)

Avoid/Use Alternative

  • acoramidis
  • Depacon (valproate sodium)
    +
    acoramidis
    1 interaction

    Avoid/Use Alternative

    valproic acid + acoramidis

    avoid combo: combo may decr. acoramidis levels, efficacy (UGT possibly induced)

  • butalbital
  • Depacon (valproate sodium)
    +
    butalbital
    1 interaction

    Avoid/Use Alternative

    valproic acid + butalbital

    avoid combo: combo may decr. valproic acid levels, efficacy; may incr. risk of CNS and respiratory depression, psychomotor impairment (UGT induced; additive effects)

  • cabotegravir
  • Depacon (valproate sodium)
    +
    cabotegravir
    1 interaction

    Avoid/Use Alternative

    valproic acid + cabotegravir

    consider alternative: combo may decr. cabotegravir levels, efficacy (UGT induced)

  • chloramphenicol
  • Depacon (valproate sodium)
    +
    chloramphenicol
    1 interaction

    Avoid/Use Alternative

    valproic acid + chloramphenicol

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cladribine oral
  • Depacon (valproate sodium)
    +
    cladribine oral
    1 interaction

    Avoid/Use Alternative

    valproic acid + cladribine oral

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • clonidine
  • Depacon (valproate sodium)
    +
    clonidine
    1 interaction

    Avoid/Use Alternative

    valproic acid + clonidine

    if ADHD use, avoid combo; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • codeine
  • Depacon (valproate sodium)
    +
    codeine
    1 interaction

    Avoid/Use Alternative

    valproic acid + codeine

    avoid combo if antitussive use; otherwise monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, codeine may decr. seizure threshold)

  • deferiprone
  • Depacon (valproate sodium)
    +
    deferiprone
    1 interaction

    Avoid/Use Alternative

    valproic acid + deferiprone

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • dolutegravir
  • Depacon (valproate sodium)
    +
    dolutegravir
    1 interaction

    Avoid/Use Alternative

    valproic acid + dolutegravir

    consider alternative: combo may decr. dolutegravir levels, efficacy (UGT induced)

  • doxylamine
  • Depacon (valproate sodium)
    +
    doxylamine
    1 interaction

    Avoid/Use Alternative

    valproic acid + doxylamine

    avoid combo if doxylamine use for pregnancy-related nausea/vomiting, otherwise caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • enoxaparin
  • Depacon (valproate sodium)
    +
    enoxaparin
    1 interaction

    Avoid/Use Alternative

    valproic acid + enoxaparin

    use alternative or monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • ertapenem
  • Depacon (valproate sodium)
    +
    ertapenem
    1 interaction

    Avoid/Use Alternative

    valproic acid + ertapenem

    use alternative or consider supplemental anticonvulsant tx: combo may decr. valproic acid levels, efficacy; may alter seizure control (mechanism unknown, glucuronide hydrolysis of valproic acid possibly inhibited; antagonistic effects, ertapenem may decr. seizure threshold)

  • estradiol (contraceptive)
  • Depacon (valproate sodium)
    +
    estradiol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    valproic acid + estradiol (contraceptive)

    use additional non-hormonal or alternative contraception during and x28 days after valproic acid tx; monitor valproic acid levels: combo may decr. estradiol levels, contraceptive efficacy; may decr. valproic acid levels, efficacy (hepatic metabolism induced, UGT induced)

  • ethanol (alcoholic beverage)
  • Depacon (valproate sodium)
    +
    ethanol (alcoholic beverage)
    1 interaction

    Avoid/Use Alternative

    valproic acid + ethanol (alcoholic beverage)

    avoid combo: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, GI or other bleeding (additive effects)

  • ethanol injection
  • Depacon (valproate sodium)
    +
    ethanol injection
    1 interaction

    Avoid/Use Alternative

    valproic acid + ethanol injection

    use alternative or monitor respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

  • ethinyl estradiol (contraceptive)
  • Depacon (valproate sodium)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Avoid/Use Alternative

    valproic acid + ethinyl estradiol (contraceptive)

    use additional non-hormonal or alternative contraception during and x28 days after valproic acid tx; monitor valproic acid levels: combo may decr. ethinyl estradiol levels, contraceptive efficacy; may decr. valproic acid levels, efficacy (UGT induced, hepatic metabolism induced)

  • fexinidazole
  • Depacon (valproate sodium)
    +
    fexinidazole
    1 interaction

    Avoid/Use Alternative

    valproic acid + fexinidazole

    use alternative or monitor valproic acid levels, CBC: combo may decr. valproic acid levels, efficacy; may incr. risk of myelosuppression (UGT possibly induced; additive effects)

  • fondaparinux
  • Depacon (valproate sodium)
    +
    fondaparinux
    1 interaction

    Avoid/Use Alternative

    valproic acid + fondaparinux

    use alternative or monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • ganciclovir
  • Depacon (valproate sodium)
    +
    ganciclovir
    1 interaction

    Avoid/Use Alternative

    valproic acid + ganciclovir

    use alternative or monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, ganciclovir may decr. seizure threshold)

  • ginkgo
  • Depacon (valproate sodium)
    +
    ginkgo
    1 interaction

    Avoid/Use Alternative

    valproic acid + ginkgo

    avoid consumption of ginkgo seeds; otherwise, monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening; may alter seizure control (additive effects; antagonistic effects, ginkgotoxin may decr. seizure threshold)

  • haloperidol
  • Depacon (valproate sodium)
    +
    haloperidol
    1 interaction

    Avoid/Use Alternative

    valproic acid + haloperidol

    avoid combo: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, haloperidol may decr. seizure threshold)

  • hydrocodone
  • Depacon (valproate sodium)
    +
    hydrocodone
    1 interaction

    Avoid/Use Alternative

    valproic acid + hydrocodone

    avoid combo if antitussive use; otherwise monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, hydrocodone may decr. seizure threshold)

  • imipenem
  • Depacon (valproate sodium)
    +
    imipenem
    1 interaction

    Avoid/Use Alternative

    valproic acid + imipenem

    use alternative or consider supplemental anticonvulsant tx: combo may decr. valproic acid levels, efficacy; may alter seizure control (mechanism unknown, glucuronide hydrolysis of valproic acid possibly inhibited; antagonistic effects, imipenem may decr. seizure threshold)

  • isocarboxazid
  • Depacon (valproate sodium)
    +
    isocarboxazid
    1 interaction

    Avoid/Use Alternative

    valproic acid + isocarboxazid

    use alternative during and x10 days after isocarboxazid use: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, isocarboxazid may decr. seizure threshold)

  • kava
  • Depacon (valproate sodium)
    +
    kava
    1 interaction

    Avoid/Use Alternative

    valproic acid + kava

    avoid combo: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • kratom
  • Depacon (valproate sodium)
    +
    kratom
    1 interaction

    Avoid/Use Alternative

    valproic acid + kratom

    use alternative or monitor respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, kratom may decr. seizure threshold)

  • letermovir
  • Depacon (valproate sodium)
    +
    letermovir
    1 interaction

    Avoid/Use Alternative

    valproic acid + letermovir

    avoid combo: combo may decr. letermovir levels, efficacy (UGT induced)

  • lorazepam
  • Depacon (valproate sodium)
    +
    lorazepam
    1 interaction

    Avoid/Use Alternative

    valproic acid + lorazepam

    avoid combo w/ lorazepam ER; monitor respiratory rate and decr. lorazepam IR or INJ dose 50%: combo may incr. lorazepam levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (UGT inhibited, additive effects)

  • meropenem
  • Depacon (valproate sodium)
    +
    meropenem
    1 interaction

    Avoid/Use Alternative

    valproic acid + meropenem

    use alternative or monitor valproic acid levels; consider supplemental anticonvulsant tx: combo may decr. valproic acid levels, efficacy; may alter seizure control (mechanism unknown, glucuronide hydrolysis of valproic acid possibly inhibited; antagonistic effects, meropenem may decr. seizure threshold)

  • metaxalone
  • Depacon (valproate sodium)
    +
    metaxalone
    1 interaction

    Avoid/Use Alternative

    valproic acid + metaxalone

    use alternative or monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • metoclopramide
  • Depacon (valproate sodium)
    +
    metoclopramide
    1 interaction

    Avoid/Use Alternative

    valproic acid + metoclopramide

    use alternative: combo may alter seizure control; may incr. risk of CNS depression, psychomotor impairment (antagonistic effects, metoclopramide may decr. seizure threshold; additive effects)

  • midazolam
  • Depacon (valproate sodium)
    +
    midazolam
    1 interaction

    Avoid/Use Alternative

    valproic acid + midazolam

    use alternative or monitor respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

  • oxybate
  • Depacon (valproate sodium)
    +
    oxybate
    1 interaction

    Avoid/Use Alternative

    valproic acid + oxybate

    use alternative or monitor respiratory rate; decr. oxybate IR dose at least 20%; no adjustment if oxybate ER form: combo may incr. oxybate levels, risk of profound CNS and respiratory depression, psychomotor impairment, hypotension, syncope, other adverse effects (hepatic metabolism possibly inhibited, additive effects)

  • phenelzine
  • Depacon (valproate sodium)
    +
    phenelzine
    1 interaction

    Avoid/Use Alternative

    valproic acid + phenelzine

    use alternative: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, phenelzine may decr. seizure threshold)

  • pivmecillinam
  • Depacon (valproate sodium)
    +
    pivmecillinam
    1 interaction

    Avoid/Use Alternative

    valproic acid + pivmecillinam

    use alternative or monitor hypocarnitinemia s/sx: combo may incr. risk of carnitine depletion (additive effects)

  • primaquine
  • Depacon (valproate sodium)
    +
    primaquine
    1 interaction

    Avoid/Use Alternative

    valproic acid + primaquine

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • promethazine
  • Depacon (valproate sodium)
    +
    promethazine
    1 interaction

    Avoid/Use Alternative

    valproic acid + promethazine

    use alternative or monitor respiratory rate; decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, promethazine may decr. seizure threshold)

  • radium Ra 223 dichloride
  • Depacon (valproate sodium)
    +
    radium Ra 223 dichloride
    1 interaction

    Avoid/Use Alternative

    valproic acid + radium Ra 223 dichloride

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ropeginterferon alfa-2b
  • Depacon (valproate sodium)
    +
    ropeginterferon alfa-2b
    1 interaction

    Avoid/Use Alternative

    valproic acid + ropeginterferon alfa-2b

    use alternative or monitor CBC: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression (additive effects)

  • sacituzumab govitecan
  • Depacon (valproate sodium)
    +
    sacituzumab govitecan
    1 interaction

    Avoid/Use Alternative

    valproic acid + sacituzumab govitecan

    avoid combo: combo may decr. SN-38 levels, efficacy; may incr. risk of myelosuppression (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan; additive effects)

  • scopolamine
  • Depacon (valproate sodium)
    +
    scopolamine
    1 interaction

    Avoid/Use Alternative

    valproic acid + scopolamine

    use alternative: combo may increase risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, scopolamine may decrease seizure threshold)

  • thalidomide
  • Depacon (valproate sodium)
    +
    thalidomide
    1 interaction

    Avoid/Use Alternative

    valproic acid + thalidomide

    use alternative or monitor CBC; consider decr. dose of one or both drugs: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thalidomide may decr. seizure threshold)

  • topiramate
  • Depacon (valproate sodium)
    +
    topiramate
    1 interaction

    Avoid/Use Alternative

    valproic acid + topiramate

    use alternative or monitor ammonia levels: combo may incr. risk of hyperammonemia, hypothermia, encephalopathy, CNS depression, psychomotor impairment (additive effects)

  • tradipitant
  • Depacon (valproate sodium)
    +
    tradipitant
    1 interaction

    Avoid/Use Alternative

    valproic acid + tradipitant

    use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • tranylcypromine
  • Depacon (valproate sodium)
    +
    tranylcypromine
    1 interaction

    Avoid/Use Alternative

    valproic acid + tranylcypromine

    use alternative: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, tranylcypromine may decr. seizure threshold)

  • trimethobenzamide
  • Depacon (valproate sodium)
    +
    trimethobenzamide
    1 interaction

    Avoid/Use Alternative

    valproic acid + trimethobenzamide

    use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • valganciclovir
  • Depacon (valproate sodium)
    +
    valganciclovir
    1 interaction

    Avoid/Use Alternative

    valproic acid + valganciclovir

    use alternative or monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, ganciclovir may decr. seizure threshold)

  • valproic acid
  • Depacon (valproate sodium)
    +
    valproic acid
    1 interaction

    Avoid/Use Alternative

    valproic acid + valproic acid

    avoid combo: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment, other adverse effects (additive effects, duplicate therapy)

  • zuranolone
  • Depacon (valproate sodium)
    +
    zuranolone
    1 interaction

    Avoid/Use Alternative

    valproic acid + zuranolone

    use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

  • abemaciclib
  • Depacon (valproate sodium)
    +
    abemaciclib
    1 interaction

    Monitor/Modify Tx

    valproic acid + abemaciclib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • abrocitinib
  • Depacon (valproate sodium)
    +
    abrocitinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + abrocitinib

    monitor platelets, bleeding s/sx, especially during abrocitinib tx initiation or if abrocitinib 200 mg/day: combo may incr. risk of bleeding (additive effects)

  • acalabrutinib
  • Depacon (valproate sodium)
    +
    acalabrutinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + acalabrutinib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

  • acetaminophen
  • Depacon (valproate sodium)
    +
    acetaminophen
    1 interaction

    Monitor/Modify Tx

    valproic acid + acetaminophen

    consider acetaminophen dose adjustment: combo may incr. acetaminophen levels, risk of adverse effects (UGT inhibited)

  • ado-trastuzumab emtansine
  • Depacon (valproate sodium)
    +
    ado-trastuzumab emtansine
    1 interaction

    Monitor/Modify Tx

    valproic acid + ado-trastuzumab emtansine

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

  • afamitresgene autoleucel
  • Depacon (valproate sodium)
    +
    afamitresgene autoleucel
    1 interaction

    Monitor/Modify Tx

    valproic acid + afamitresgene autoleucel

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • afatinib
  • Depacon (valproate sodium)
    +
    afatinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + afatinib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • albendazole
  • Depacon (valproate sodium)
    +
    albendazole
    1 interaction

    Monitor/Modify Tx

    valproic acid + albendazole

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • aldesleukin
  • Depacon (valproate sodium)
    +
    aldesleukin
    1 interaction

    Monitor/Modify Tx

    valproic acid + aldesleukin

    monitor CBC; withhold aldesleukin if mod-severe somnolence occurs: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aldesleukin may decr. seizure threshold)

  • alemtuzumab
  • Depacon (valproate sodium)
    +
    alemtuzumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + alemtuzumab

    monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

  • alfentanil
  • Depacon (valproate sodium)
    +
    alfentanil
    1 interaction

    Monitor/Modify Tx

    valproic acid + alfentanil

    monitor BP, respiratory rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension; may alter seizure control (additive effects; antagonistic effects, alfentanil may decr. seizure threshold)

  • allopurinol
  • Depacon (valproate sodium)
    +
    allopurinol
    1 interaction

    Monitor/Modify Tx

    valproic acid + allopurinol

    monitor CBC: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression (additive effects)

  • alpha-tocopherol (vitamin E)
  • Depacon (valproate sodium)
    +
    alpha-tocopherol (vitamin E)
    1 interaction

    Monitor/Modify Tx

    valproic acid + alpha-tocopherol (vitamin E)

    monitor bleeding signs/symptoms, especially with alpha-tocopherol doses >800 units/day: combo may increase risk of bleeding (additive effects)

  • alprazolam
  • Depacon (valproate sodium)
    +
    alprazolam
    1 interaction

    Monitor/Modify Tx

    valproic acid + alprazolam

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • alprostadil intracavernous
  • Depacon (valproate sodium)
    +
    alprostadil intracavernous
    1 interaction

    Monitor/Modify Tx

    valproic acid + alprostadil intracavernous

    monitor injection site bleeding signs/symptoms: combo may increase risk of localized bleeding (additive effects)

  • alprostadil intravenous
  • Depacon (valproate sodium)
    +
    alprostadil intravenous
    1 interaction

    Monitor/Modify Tx

    valproic acid + alprostadil intravenous

    monitor bleeding signs/symptoms: combo may increase risk of bleeding (additive effects)

  • alteplase
  • Depacon (valproate sodium)
    +
    alteplase
    1 interaction

    Monitor/Modify Tx

    valproic acid + alteplase

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • aminophylline
  • Depacon (valproate sodium)
    +
    aminophylline
    1 interaction

    Monitor/Modify Tx

    valproic acid + aminophylline

    monitor theophylline levels: combo may decr. theophylline levels, efficacy; may alter seizure control (hepatic metabolism induced, aminophylline converted to theophylline; antagonistic effects, theophylline may decr. seizure threshold)

  • amitriptyline
  • Depacon (valproate sodium)
    +
    amitriptyline
    1 interaction

    Monitor/Modify Tx

    valproic acid + amitriptyline

    monitor amitriptyline levels: combo may incr. amitriptyline levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metabolism possibly inhibited, additive effects; antagonistic effects, amitriptyline may decr. seizure threshold)

  • anacaulase topical
  • Depacon (valproate sodium)
    +
    anacaulase topical
    1 interaction

    Monitor/Modify Tx

    valproic acid + anacaulase topical

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • anagrelide
  • Depacon (valproate sodium)
    +
    anagrelide
    1 interaction

    Monitor/Modify Tx

    valproic acid + anagrelide

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • anti-thymocyte globulin
  • Depacon (valproate sodium)
    +
    anti-thymocyte globulin
    1 interaction

    Monitor/Modify Tx

    valproic acid + anti-thymocyte globulin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • antithrombin
  • Depacon (valproate sodium)
    +
    antithrombin
    1 interaction

    Monitor/Modify Tx

    valproic acid + antithrombin

    monitor bleeding s/sx: combo may incr. risk of bleeding, including severe (additive effects)

  • apixaban
  • Depacon (valproate sodium)
    +
    apixaban
    1 interaction

    Monitor/Modify Tx

    valproic acid + apixaban

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • argatroban
  • Depacon (valproate sodium)
    +
    argatroban
    1 interaction

    Monitor/Modify Tx

    valproic acid + argatroban

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • arsenic trioxide
  • Depacon (valproate sodium)
    +
    arsenic trioxide
    1 interaction

    Monitor/Modify Tx

    valproic acid + arsenic trioxide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • asciminib
  • Depacon (valproate sodium)
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    valproic acid + asciminib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • asparaginase
  • Depacon (valproate sodium)
    +
    asparaginase
    1 interaction

    Monitor/Modify Tx

    valproic acid + asparaginase

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • aspirin
  • Depacon (valproate sodium)
    +
    aspirin
    1 interaction

    Monitor/Modify Tx

    valproic acid + aspirin

    monitor bleeding s/sx, valproic acid levels: combo may incr. valproic acid levels, risk of GI or other bleeding (including life-threatening), other adverse effects (additive effects; mechanism unknown)

  • atidarsagene autotemcel
  • Depacon (valproate sodium)
    +
    atidarsagene autotemcel
    1 interaction

    Monitor/Modify Tx

    valproic acid + atidarsagene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • auranofin
  • Depacon (valproate sodium)
    +
    auranofin
    1 interaction

    Monitor/Modify Tx

    valproic acid + auranofin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • avapritinib
  • Depacon (valproate sodium)
    +
    avapritinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + avapritinib

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • axicabtagene ciloleucel
  • Depacon (valproate sodium)
    +
    axicabtagene ciloleucel
    1 interaction

    Monitor/Modify Tx

    valproic acid + axicabtagene ciloleucel

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, axicabtagene ciloleucel may decr. seizure threshold)

  • axitinib
  • Depacon (valproate sodium)
    +
    axitinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + axitinib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • azacitidine
  • Depacon (valproate sodium)
    +
    azacitidine
    1 interaction

    Monitor/Modify Tx

    valproic acid + azacitidine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • azathioprine
  • Depacon (valproate sodium)
    +
    azathioprine
    1 interaction

    Monitor/Modify Tx

    valproic acid + azathioprine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • baclofen intrathecal
  • Depacon (valproate sodium)
    +
    baclofen intrathecal
    1 interaction

    Monitor/Modify Tx

    valproic acid + baclofen intrathecal

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, baclofen may decr. seizure threshold)

  • balsalazide
  • Depacon (valproate sodium)
    +
    balsalazide
    1 interaction

    Monitor/Modify Tx

    valproic acid + balsalazide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • baricitinib
  • Depacon (valproate sodium)
    +
    baricitinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + baricitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • belantamab mafodotin
  • Depacon (valproate sodium)
    +
    belantamab mafodotin
    1 interaction

    Monitor/Modify Tx

    valproic acid + belantamab mafodotin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • belinostat
  • Depacon (valproate sodium)
    +
    belinostat
    1 interaction

    Monitor/Modify Tx

    valproic acid + belinostat

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • bendamustine
  • Depacon (valproate sodium)
    +
    bendamustine
    1 interaction

    Monitor/Modify Tx

    valproic acid + bendamustine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • benznidazole
  • Depacon (valproate sodium)
    +
    benznidazole
    1 interaction

    Monitor/Modify Tx

    valproic acid + benznidazole

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • betibeglogene autotemcel
  • Depacon (valproate sodium)
    +
    betibeglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    valproic acid + betibeglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • bevacizumab
  • Depacon (valproate sodium)
    +
    bevacizumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + bevacizumab

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

  • bexarotene
  • Depacon (valproate sodium)
    +
    bexarotene
    1 interaction

    Monitor/Modify Tx

    valproic acid + bexarotene

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • binimetinib
  • Depacon (valproate sodium)
    +
    binimetinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + binimetinib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • bivalirudin
  • Depacon (valproate sodium)
    +
    bivalirudin
    1 interaction

    Monitor/Modify Tx

    valproic acid + bivalirudin

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • blinatumomab
  • Depacon (valproate sodium)
    +
    blinatumomab
    1 interaction

    Monitor/Modify Tx

    valproic acid + blinatumomab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • bortezomib
  • Depacon (valproate sodium)
    +
    bortezomib
    1 interaction

    Monitor/Modify Tx

    valproic acid + bortezomib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • bosutinib
  • Depacon (valproate sodium)
    +
    bosutinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + bosutinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • brentuximab vedotin
  • Depacon (valproate sodium)
    +
    brentuximab vedotin
    1 interaction

    Monitor/Modify Tx

    valproic acid + brentuximab vedotin

    monitor CBC: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

  • brexucabtagene autoleucel
  • Depacon (valproate sodium)
    +
    brexucabtagene autoleucel
    1 interaction

    Monitor/Modify Tx

    valproic acid + brexucabtagene autoleucel

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, brexucabtagene autoleucel may decr. seizure threshold)

  • bromelain
  • Depacon (valproate sodium)
    +
    bromelain
    1 interaction

    Monitor/Modify Tx

    valproic acid + bromelain

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • bromfenac ophthalmic
  • Depacon (valproate sodium)
    +
    bromfenac ophthalmic
    1 interaction

    Monitor/Modify Tx

    valproic acid + bromfenac ophthalmic

    monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

  • buprenorphine
  • Depacon (valproate sodium)
    +
    buprenorphine
    1 interaction

    Monitor/Modify Tx

    valproic acid + buprenorphine

    monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, buprenorphine may decr. seizure threshold)

  • busulfan
  • Depacon (valproate sodium)
    +
    busulfan
    1 interaction

    Monitor/Modify Tx

    valproic acid + busulfan

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, busulfan may decr. seizure threshold)

  • butorphanol
  • Depacon (valproate sodium)
    +
    butorphanol
    1 interaction

    Monitor/Modify Tx

    valproic acid + butorphanol

    monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, butorphanol may decr. seizure threshold)

  • cabazitaxel
  • Depacon (valproate sodium)
    +
    cabazitaxel
    1 interaction

    Monitor/Modify Tx

    valproic acid + cabazitaxel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

  • cabozantinib
  • Depacon (valproate sodium)
    +
    cabozantinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + cabozantinib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • caffeine citrate
  • Depacon (valproate sodium)
    +
    caffeine citrate
    1 interaction

    Monitor/Modify Tx

    valproic acid + caffeine citrate

    monitor caffeine levels: combo may decr. caffeine levels, efficacy (hepatic metabolism induced)

  • calaspargase
  • Depacon (valproate sodium)
    +
    calaspargase
    1 interaction

    Monitor/Modify Tx

    valproic acid + calaspargase

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • cangrelor
  • Depacon (valproate sodium)
    +
    cangrelor
    1 interaction

    Monitor/Modify Tx

    valproic acid + cangrelor

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • cannabidiol
  • Depacon (valproate sodium)
    +
    cannabidiol
    1 interaction

    Monitor/Modify Tx

    valproic acid + cannabidiol

    monitor ALT, AST, total bilirubin, ammonia levels: combo may incr. risk of CNS depression, psychomotor impairment, hepatocellular injury, hyperammonemia (additive effects)

  • capecitabine
  • Depacon (valproate sodium)
    +
    capecitabine
    1 interaction

    Monitor/Modify Tx

    valproic acid + capecitabine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • caplacizumab
  • Depacon (valproate sodium)
    +
    caplacizumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + caplacizumab

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • carbamazepine
  • Depacon (valproate sodium)
    +
    carbamazepine
    1 interaction

    Monitor/Modify Tx

    valproic acid + carbamazepine

    monitor levels of both drugs: combo may decr. valproic acid levels, efficacy; may incr. carbamazepine active metabolite levels, risk of CNS depression, psychomotor impairment, other adverse effects (UGT induced; epoxide hydrolase inhibited, additive effects)

  • carboplatin
  • Depacon (valproate sodium)
    +
    carboplatin
    1 interaction

    Monitor/Modify Tx

    valproic acid + carboplatin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • carfilzomib
  • Depacon (valproate sodium)
    +
    carfilzomib
    1 interaction

    Monitor/Modify Tx

    valproic acid + carfilzomib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

  • carglumic acid
  • Depacon (valproate sodium)
    +
    carglumic acid
    1 interaction

    Monitor/Modify Tx

    valproic acid + carglumic acid

    monitor ammonia levels: combo may decr. carglumic acid efficacy (antagonistic effects)

  • carmustine
  • Depacon (valproate sodium)
    +
    carmustine
    1 interaction

    Monitor/Modify Tx

    valproic acid + carmustine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • celecoxib
  • Depacon (valproate sodium)
    +
    celecoxib
    1 interaction

    Monitor/Modify Tx

    valproic acid + celecoxib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • chlorambucil
  • Depacon (valproate sodium)
    +
    chlorambucil
    1 interaction

    Monitor/Modify Tx

    valproic acid + chlorambucil

    monitor CBC, consider chlorambucil dose adjustment: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, chlorambucil may decr. seizure threshold)

  • chlordiazepoxide
  • Depacon (valproate sodium)
    +
    chlordiazepoxide
    1 interaction

    Monitor/Modify Tx

    valproic acid + chlordiazepoxide

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • chlorpromazine
  • Depacon (valproate sodium)
    +
    chlorpromazine
    1 interaction

    Monitor/Modify Tx

    valproic acid + chlorpromazine

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, chlorpromazine may decr. seizure threshold)

  • cholestyramine
  • Depacon (valproate sodium)
    +
    cholestyramine
    1 interaction

    Monitor/Modify Tx

    valproic acid + cholestyramine

    separate admin. w/ oral valproic acid by 3h: combo may decr. valproic acid levels, efficacy (absorption decreased/delayed)

  • cidofovir
  • Depacon (valproate sodium)
    +
    cidofovir
    1 interaction

    Monitor/Modify Tx

    valproic acid + cidofovir

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cilostazol
  • Depacon (valproate sodium)
    +
    cilostazol
    1 interaction

    Monitor/Modify Tx

    valproic acid + cilostazol

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • ciltacabtagene autoleucel
  • Depacon (valproate sodium)
    +
    ciltacabtagene autoleucel
    1 interaction

    Monitor/Modify Tx

    valproic acid + ciltacabtagene autoleucel

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, ciltacabtagene autoleucel may decr. seizure threshold)

  • cisplatin
  • Depacon (valproate sodium)
    +
    cisplatin
    1 interaction

    Monitor/Modify Tx

    valproic acid + cisplatin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • citalopram
  • Depacon (valproate sodium)
    +
    citalopram
    1 interaction

    Monitor/Modify Tx

    valproic acid + citalopram

    monitor bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, bleeding, including life-threatening; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, citalopram may decr. seizure threshold)

  • cladribine injection
  • Depacon (valproate sodium)
    +
    cladribine injection
    1 interaction

    Monitor/Modify Tx

    valproic acid + cladribine injection

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • clarithromycin
  • Depacon (valproate sodium)
    +
    clarithromycin
    1 interaction

    Monitor/Modify Tx

    valproic acid + clarithromycin

    monitor valproic acid levels: combo may incr. valproic acid levels, risk of adverse effects (mechanism unknown, hepatic metabolism possibly inhibited)

  • clobazam
  • Depacon (valproate sodium)
    +
    clobazam
    1 interaction

    Monitor/Modify Tx

    valproic acid + clobazam

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • clofarabine
  • Depacon (valproate sodium)
    +
    clofarabine
    1 interaction

    Monitor/Modify Tx

    valproic acid + clofarabine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • clonazepam
  • Depacon (valproate sodium)
    +
    clonazepam
    1 interaction

    Monitor/Modify Tx

    valproic acid + clonazepam

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment; may incr. risk of absence seizures (additive effects; mechanism unknown)

  • clopidogrel
  • Depacon (valproate sodium)
    +
    clopidogrel
    1 interaction

    Monitor/Modify Tx

    valproic acid + clopidogrel

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • clorazepate
  • Depacon (valproate sodium)
    +
    clorazepate
    1 interaction

    Monitor/Modify Tx

    valproic acid + clorazepate

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • clozapine
  • Depacon (valproate sodium)
    +
    clozapine
    1 interaction

    Monitor/Modify Tx

    valproic acid + clozapine

    monitor CBC: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression; may alter seizure control (additive effects; antagonistic effects, clozapine may decr. seizure threshold)

  • colchicine
  • Depacon (valproate sodium)
    +
    colchicine
    1 interaction

    Monitor/Modify Tx

    valproic acid + colchicine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • collagenase clostridium histolyticum
  • Depacon (valproate sodium)
    +
    collagenase clostridium histolyticum
    1 interaction

    Monitor/Modify Tx

    valproic acid + collagenase clostridium histolyticum

    monitor injection site bleeding s/sx: combo may incr. risk of localized bleeding, including severe (additive effects)

  • copanlisib
  • Depacon (valproate sodium)
    +
    copanlisib
    1 interaction

    Monitor/Modify Tx

    valproic acid + copanlisib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • copper histidinate
  • Depacon (valproate sodium)
    +
    copper histidinate
    1 interaction

    Monitor/Modify Tx

    valproic acid + copper histidinate

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • crizotinib
  • Depacon (valproate sodium)
    +
    crizotinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + crizotinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cyclophosphamide
  • Depacon (valproate sodium)
    +
    cyclophosphamide
    1 interaction

    Monitor/Modify Tx

    valproic acid + cyclophosphamide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cysteamine
  • Depacon (valproate sodium)
    +
    cysteamine
    1 interaction

    Monitor/Modify Tx

    valproic acid + cysteamine

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding (additive effects)

  • cytarabine
  • Depacon (valproate sodium)
    +
    cytarabine
    1 interaction

    Monitor/Modify Tx

    valproic acid + cytarabine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • dabigatran
  • Depacon (valproate sodium)
    +
    dabigatran
    1 interaction

    Monitor/Modify Tx

    valproic acid + dabigatran

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • dacarbazine
  • Depacon (valproate sodium)
    +
    dacarbazine
    1 interaction

    Monitor/Modify Tx

    valproic acid + dacarbazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • dactinomycin
  • Depacon (valproate sodium)
    +
    dactinomycin
    1 interaction

    Monitor/Modify Tx

    valproic acid + dactinomycin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • dalteparin
  • Depacon (valproate sodium)
    +
    dalteparin
    1 interaction

    Monitor/Modify Tx

    valproic acid + dalteparin

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • danshen
  • Depacon (valproate sodium)
    +
    danshen
    1 interaction

    Monitor/Modify Tx

    valproic acid + danshen

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • dapsone
  • Depacon (valproate sodium)
    +
    dapsone
    1 interaction

    Monitor/Modify Tx

    valproic acid + dapsone

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • daratumumab
  • Depacon (valproate sodium)
    +
    daratumumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + daratumumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • daridorexant
  • Depacon (valproate sodium)
    +
    daridorexant
    1 interaction

    Monitor/Modify Tx

    valproic acid + daridorexant

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • dasatinib
  • Depacon (valproate sodium)
    +
    dasatinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + dasatinib

    monitor bleeding s/sx, CBC: combo may incr. risk of GI or other bleeding (including life-threatening), myelosuppression (additive effects)

  • daunorubicin
  • Depacon (valproate sodium)
    +
    daunorubicin
    1 interaction

    Monitor/Modify Tx

    valproic acid + daunorubicin

    monitor CBC, bleeding signs/symptoms: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

  • decitabine
  • Depacon (valproate sodium)
    +
    decitabine
    1 interaction

    Monitor/Modify Tx

    valproic acid + decitabine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • deferasirox
  • Depacon (valproate sodium)
    +
    deferasirox
    1 interaction

    Monitor/Modify Tx

    valproic acid + deferasirox

    monitor serum ferritin levels, bleeding s/sx, CBC: combo may decr. deferasirox levels, efficacy; may incr. risk of GI or other bleeding (including life-threatening), myelosuppression (UGT induced; additive effects)

  • defibrotide
  • Depacon (valproate sodium)
    +
    defibrotide
    1 interaction

    Monitor/Modify Tx

    valproic acid + defibrotide

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • desflurane
  • Depacon (valproate sodium)
    +
    desflurane
    1 interaction

    Monitor/Modify Tx

    valproic acid + desflurane

    monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • desvenlafaxine
  • Depacon (valproate sodium)
    +
    desvenlafaxine
    1 interaction

    Monitor/Modify Tx

    valproic acid + desvenlafaxine

    monitor bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, bleeding, including life-threatening; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, desvenlafaxine may decr. seizure threshold)

  • deuruxolitinib
  • Depacon (valproate sodium)
    +
    deuruxolitinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + deuruxolitinib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, serious infection, GI or other bleeding (additive effects)

  • dexmedetomidine
  • Depacon (valproate sodium)
    +
    dexmedetomidine
    1 interaction

    Monitor/Modify Tx

    valproic acid + dexmedetomidine

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • dexmedetomidine injection
  • Depacon (valproate sodium)
    +
    dexmedetomidine injection
    1 interaction

    Monitor/Modify Tx

    valproic acid + dexmedetomidine injection

    monitor respiratory rate, consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • dexrazoxane
  • Depacon (valproate sodium)
    +
    dexrazoxane
    1 interaction

    Monitor/Modify Tx

    valproic acid + dexrazoxane

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • diazepam
  • Depacon (valproate sodium)
    +
    diazepam
    1 interaction

    Monitor/Modify Tx

    valproic acid + diazepam

    monitor respiratory rate, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

  • diclofenac
  • Depacon (valproate sodium)
    +
    diclofenac
    1 interaction

    Monitor/Modify Tx

    valproic acid + diclofenac

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • diclofenac ophthalmic
  • Depacon (valproate sodium)
    +
    diclofenac ophthalmic
    1 interaction

    Monitor/Modify Tx

    valproic acid + diclofenac ophthalmic

    monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

  • diclofenac topical
  • Depacon (valproate sodium)
    +
    diclofenac topical
    1 interaction

    Monitor/Modify Tx

    valproic acid + diclofenac topical

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • diflunisal
  • Depacon (valproate sodium)
    +
    diflunisal
    1 interaction

    Monitor/Modify Tx

    valproic acid + diflunisal

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • dihydrocodeine
  • Depacon (valproate sodium)
    +
    dihydrocodeine
    1 interaction

    Monitor/Modify Tx

    valproic acid + dihydrocodeine

    monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, dihydrocodeine may decr. seizure threshold)

  • dimethyl fumarate
  • Depacon (valproate sodium)
    +
    dimethyl fumarate
    1 interaction

    Monitor/Modify Tx

    valproic acid + dimethyl fumarate

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • dinutuximab
  • Depacon (valproate sodium)
    +
    dinutuximab
    1 interaction

    Monitor/Modify Tx

    valproic acid + dinutuximab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • diosmin
  • Depacon (valproate sodium)
    +
    diosmin
    1 interaction

    Monitor/Modify Tx

    valproic acid + diosmin

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • dipyridamole
  • Depacon (valproate sodium)
    +
    dipyridamole
    1 interaction

    Monitor/Modify Tx

    valproic acid + dipyridamole

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • diroximel fumarate
  • Depacon (valproate sodium)
    +
    diroximel fumarate
    1 interaction

    Monitor/Modify Tx

    valproic acid + diroximel fumarate

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • docetaxel
  • Depacon (valproate sodium)
    +
    docetaxel
    1 interaction

    Monitor/Modify Tx

    valproic acid + docetaxel

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • dostarlimab
  • Depacon (valproate sodium)
    +
    dostarlimab
    1 interaction

    Monitor/Modify Tx

    valproic acid + dostarlimab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • doxorubicin
  • Depacon (valproate sodium)
    +
    doxorubicin
    1 interaction

    Monitor/Modify Tx

    valproic acid + doxorubicin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • droperidol
  • Depacon (valproate sodium)
    +
    droperidol
    1 interaction

    Monitor/Modify Tx

    valproic acid + droperidol

    decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • duloxetine
  • Depacon (valproate sodium)
    +
    duloxetine
    1 interaction

    Monitor/Modify Tx

    valproic acid + duloxetine

    monitor bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, bleeding, including life-threatening; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, duloxetine may decr. seizure threshold)

  • duvelisib
  • Depacon (valproate sodium)
    +
    duvelisib
    1 interaction

    Monitor/Modify Tx

    valproic acid + duvelisib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • edoxaban
  • Depacon (valproate sodium)
    +
    edoxaban
    1 interaction

    Monitor/Modify Tx

    valproic acid + edoxaban

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • eflornithine
  • Depacon (valproate sodium)
    +
    eflornithine
    1 interaction

    Monitor/Modify Tx

    valproic acid + eflornithine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • elivaldogene autotemcel
  • Depacon (valproate sodium)
    +
    elivaldogene autotemcel
    1 interaction

    Monitor/Modify Tx

    valproic acid + elivaldogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, elivaldogene autotemcel may decr. seizure threshold)

  • elranatamab
  • Depacon (valproate sodium)
    +
    elranatamab
    1 interaction

    Monitor/Modify Tx

    valproic acid + elranatamab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • encorafenib
  • Depacon (valproate sodium)
    +
    encorafenib
    1 interaction

    Monitor/Modify Tx

    valproic acid + encorafenib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • enfortumab vedotin
  • Depacon (valproate sodium)
    +
    enfortumab vedotin
    1 interaction

    Monitor/Modify Tx

    valproic acid + enfortumab vedotin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • entrectinib
  • Depacon (valproate sodium)
    +
    entrectinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + entrectinib

    monitor CBC: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment (additive effects)

  • epcoritamab
  • Depacon (valproate sodium)
    +
    epcoritamab
    1 interaction

    Monitor/Modify Tx

    valproic acid + epcoritamab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • epirubicin
  • Depacon (valproate sodium)
    +
    epirubicin
    1 interaction

    Monitor/Modify Tx

    valproic acid + epirubicin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • epoprostenol
  • Depacon (valproate sodium)
    +
    epoprostenol
    1 interaction

    Monitor/Modify Tx

    valproic acid + epoprostenol

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • eptifibatide
  • Depacon (valproate sodium)
    +
    eptifibatide
    1 interaction

    Monitor/Modify Tx

    valproic acid + eptifibatide

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • eribulin
  • Depacon (valproate sodium)
    +
    eribulin
    1 interaction

    Monitor/Modify Tx

    valproic acid + eribulin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • erlotinib
  • Depacon (valproate sodium)
    +
    erlotinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + erlotinib

    monitor bleeding s/sx: combo may decr. erlotinib levels, efficacy; may incr. risk of GI or other bleeding, including life-threatening (hepatic metabolism induced; additive effects)

  • erythromycin
  • Depacon (valproate sodium)
    +
    erythromycin
    1 interaction

    Monitor/Modify Tx

    valproic acid + erythromycin

    monitor valproic acid levels: combo may incr. valproic acid levels, risk of adverse effects (mechanism unknown, hepatic metabolism possibly inhibited)

  • escitalopram
  • Depacon (valproate sodium)
    +
    escitalopram
    1 interaction

    Monitor/Modify Tx

    valproic acid + escitalopram

    monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, escitalopram may decr. seizure threshold)

  • esketamine
  • Depacon (valproate sodium)
    +
    esketamine
    1 interaction

    Monitor/Modify Tx

    valproic acid + esketamine

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • estazolam
  • Depacon (valproate sodium)
    +
    estazolam
    1 interaction

    Monitor/Modify Tx

    valproic acid + estazolam

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • estradiol (hormone replacement)
  • Depacon (valproate sodium)
    +
    estradiol (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    valproic acid + estradiol (hormone replacement)

    monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

  • estrogens, conjugated (hormone replacement)
  • Depacon (valproate sodium)
    +
    estrogens, conjugated (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    valproic acid + estrogens, conjugated (hormone replacement)

    monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

  • estrogens, esterified (hormone replacement)
  • Depacon (valproate sodium)
    +
    estrogens, esterified (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    valproic acid + estrogens, esterified (hormone replacement)

    monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

  • eszopiclone
  • Depacon (valproate sodium)
    +
    eszopiclone
    1 interaction

    Monitor/Modify Tx

    valproic acid + eszopiclone

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • ethanol (in some formulations)
  • Depacon (valproate sodium)
    +
    ethanol (in some formulations)
    1 interaction

    Monitor/Modify Tx

    valproic acid + ethanol (in some formulations)

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • ethinyl estradiol (hormone replacement)
  • Depacon (valproate sodium)
    +
    ethinyl estradiol (hormone replacement)
    1 interaction

    Monitor/Modify Tx

    valproic acid + ethinyl estradiol (hormone replacement)

    monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

  • ethosuximide
  • Depacon (valproate sodium)
    +
    ethosuximide
    1 interaction

    Monitor/Modify Tx

    valproic acid + ethosuximide

    monitor ethosuximide levels: combo may incr. ethosuximide levels, risk of toxicity; may incr. risk of CNS depression, psychomotor impairment (hepatic metabolism inhibited; additive effects)

  • etodolac
  • Depacon (valproate sodium)
    +
    etodolac
    1 interaction

    Monitor/Modify Tx

    valproic acid + etodolac

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • etomidate
  • Depacon (valproate sodium)
    +
    etomidate
    1 interaction

    Monitor/Modify Tx

    valproic acid + etomidate

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • etoposide
  • Depacon (valproate sodium)
    +
    etoposide
    1 interaction

    Monitor/Modify Tx

    valproic acid + etoposide

    monitor CBC: combo may incr. risk of myelosuppression; may decr. etoposide levels, efficacy (additive effects; mechanism unknown, hepatic metabolism possibly induced)

  • etuvetidigene autotemcel
  • Depacon (valproate sodium)
    +
    etuvetidigene autotemcel
    1 interaction

    Monitor/Modify Tx

    valproic acid + etuvetidigene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • evening primrose oil
  • Depacon (valproate sodium)
    +
    evening primrose oil
    1 interaction

    Monitor/Modify Tx

    valproic acid + evening primrose oil

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • everolimus
  • Depacon (valproate sodium)
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    valproic acid + everolimus

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • exagamglogene autotemcel
  • Depacon (valproate sodium)
    +
    exagamglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    valproic acid + exagamglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • fam-trastuzumab deruxtecan
  • Depacon (valproate sodium)
    +
    fam-trastuzumab deruxtecan
    1 interaction

    Monitor/Modify Tx

    valproic acid + fam-trastuzumab deruxtecan

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fedratinib
  • Depacon (valproate sodium)
    +
    fedratinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + fedratinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • felbamate
  • Depacon (valproate sodium)
    +
    felbamate
    1 interaction

    Monitor/Modify Tx

    valproic acid + felbamate

    monitor valproic acid levels: combo may incr. valproic acid levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

  • fenoprofen
  • Depacon (valproate sodium)
    +
    fenoprofen
    1 interaction

    Monitor/Modify Tx

    valproic acid + fenoprofen

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • fentanyl
  • Depacon (valproate sodium)
    +
    fentanyl
    1 interaction

    Monitor/Modify Tx

    valproic acid + fentanyl

    monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, fentanyl may decr. seizure threshold)

  • fenugreek
  • Depacon (valproate sodium)
    +
    fenugreek
    1 interaction

    Monitor/Modify Tx

    valproic acid + fenugreek

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • floxuridine
  • Depacon (valproate sodium)
    +
    floxuridine
    1 interaction

    Monitor/Modify Tx

    valproic acid + floxuridine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • flucytosine
  • Depacon (valproate sodium)
    +
    flucytosine
    1 interaction

    Monitor/Modify Tx

    valproic acid + flucytosine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fludarabine
  • Depacon (valproate sodium)
    +
    fludarabine
    1 interaction

    Monitor/Modify Tx

    valproic acid + fludarabine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fluorouracil
  • Depacon (valproate sodium)
    +
    fluorouracil
    1 interaction

    Monitor/Modify Tx

    valproic acid + fluorouracil

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fluoxetine
  • Depacon (valproate sodium)
    +
    fluoxetine
    1 interaction

    Monitor/Modify Tx

    valproic acid + fluoxetine

    monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, fluoxetine may decr. seizure threshold)

  • fluphenazine
  • Depacon (valproate sodium)
    +
    fluphenazine
    1 interaction

    Monitor/Modify Tx

    valproic acid + fluphenazine

    monitor CBC; consider decr. dose of one or both drugs: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, fluphenazine may decr. seizure threshold)

  • flurazepam
  • Depacon (valproate sodium)
    +
    flurazepam
    1 interaction

    Monitor/Modify Tx

    valproic acid + flurazepam

    monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • flurbiprofen
  • Depacon (valproate sodium)
    +
    flurbiprofen
    1 interaction

    Monitor/Modify Tx

    valproic acid + flurbiprofen

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • flurbiprofen ophthalmic
  • Depacon (valproate sodium)
    +
    flurbiprofen ophthalmic
    1 interaction

    Monitor/Modify Tx

    valproic acid + flurbiprofen ophthalmic

    monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

  • fluvoxamine
  • Depacon (valproate sodium)
    +
    fluvoxamine
    1 interaction

    Monitor/Modify Tx

    valproic acid + fluvoxamine

    monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, fluvoxamine may decr. seizure threshold)

  • foscarnet
  • Depacon (valproate sodium)
    +
    foscarnet
    1 interaction

    Monitor/Modify Tx

    valproic acid + foscarnet

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, foscarnet may decr. seizure threshold)

  • fosfomycin injection
  • Depacon (valproate sodium)
    +
    fosfomycin injection
    1 interaction

    Monitor/Modify Tx

    valproic acid + fosfomycin injection

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fosphenytoin
  • Depacon (valproate sodium)
    +
    fosphenytoin
    1 interaction

    Monitor/Modify Tx

    valproic acid + fosphenytoin

    monitor levels of both drugs, ammonia levels: combo may decr. valproic acid levels, efficacy; may incr. or decr. phenytoin levels, incr. risk of toxicity or decr. efficacy; may incr. risk of CNS depression, psychomotor impairment, hyperammonemia (UGT induced; hepatic metabolism altered; additive effects)

  • fostamatinib
  • Depacon (valproate sodium)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + fostamatinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fruquintinib
  • Depacon (valproate sodium)
    +
    fruquintinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + fruquintinib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • gabapentin
  • Depacon (valproate sodium)
    +
    gabapentin
    1 interaction

    Monitor/Modify Tx

    valproic acid + gabapentin

    monitor respiratory rate; consider decreasing gabapentin dose: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

  • gabapentin enacarbil
  • Depacon (valproate sodium)
    +
    gabapentin enacarbil
    1 interaction

    Monitor/Modify Tx

    valproic acid + gabapentin enacarbil

    monitor respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

  • ganaxolone
  • Depacon (valproate sodium)
    +
    ganaxolone
    1 interaction

    Monitor/Modify Tx

    valproic acid + ganaxolone

    consider decr. ganaxolone maintenance dose when starting valproic acid: combo may incr. ganaxolone levels, risk of CNS depression, psychomotor impairment, other adverse effects (UGT possibly inhibited, additive effects)

  • garlic
  • Depacon (valproate sodium)
    +
    garlic
    1 interaction

    Monitor/Modify Tx

    valproic acid + garlic

    monitor bleeding s/sx, especially w/ supplemental garlic; dietary intake OK: combo may incr. risk of GI or other bleeding (additive effects)

  • gefitinib
  • Depacon (valproate sodium)
    +
    gefitinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + gefitinib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • gemcitabine
  • Depacon (valproate sodium)
    +
    gemcitabine
    1 interaction

    Monitor/Modify Tx

    valproic acid + gemcitabine

    monitor CBC; risk may be lower w/ intravesical gemcitabine administration: combo may incr. risk of myelosuppression (additive effects)

  • gemtuzumab ozogamicin
  • Depacon (valproate sodium)
    +
    gemtuzumab ozogamicin
    1 interaction

    Monitor/Modify Tx

    valproic acid + gemtuzumab ozogamicin

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

  • givinostat
  • Depacon (valproate sodium)
    +
    givinostat
    1 interaction

    Monitor/Modify Tx

    valproic acid + givinostat

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • glasdegib
  • Depacon (valproate sodium)
    +
    glasdegib
    1 interaction

    Monitor/Modify Tx

    valproic acid + glasdegib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • glofitamab
  • Depacon (valproate sodium)
    +
    glofitamab
    1 interaction

    Monitor/Modify Tx

    valproic acid + glofitamab

    monitor CBC: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression (additive effects)

  • glycerol phenylbutyrate
  • Depacon (valproate sodium)
    +
    glycerol phenylbutyrate
    1 interaction

    Monitor/Modify Tx

    valproic acid + glycerol phenylbutyrate

    monitor ammonia levels: combo may decr. glycerol phenylbutyrate efficacy (antagonistic effects)

  • heparin
  • Depacon (valproate sodium)
    +
    heparin
    1 interaction

    Monitor/Modify Tx

    valproic acid + heparin

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • hydrocortisone
  • Depacon (valproate sodium)
    +
    hydrocortisone
    1 interaction

    Monitor/Modify Tx

    valproic acid + hydrocortisone

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding (additive effects)

  • hydromorphone
  • Depacon (valproate sodium)
    +
    hydromorphone
    1 interaction

    Monitor/Modify Tx

    valproic acid + hydromorphone

    monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, hydromorphone may decr. seizure threshold)

  • hydroxychloroquine
  • Depacon (valproate sodium)
    +
    hydroxychloroquine
    1 interaction

    Monitor/Modify Tx

    valproic acid + hydroxychloroquine

    monitor CBC; caution advised if seizure disorder use: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, hydroxychloroquine may decr. seizure threshold)

  • hydroxyurea
  • Depacon (valproate sodium)
    +
    hydroxyurea
    1 interaction

    Monitor/Modify Tx

    valproic acid + hydroxyurea

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • hydroxyzine
  • Depacon (valproate sodium)
    +
    hydroxyzine
    1 interaction

    Monitor/Modify Tx

    valproic acid + hydroxyzine

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • ibritumomab tiuxetan
  • Depacon (valproate sodium)
    +
    ibritumomab tiuxetan
    1 interaction

    Monitor/Modify Tx

    valproic acid + ibritumomab tiuxetan

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ibrutinib
  • Depacon (valproate sodium)
    +
    ibrutinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + ibrutinib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

  • ibuprofen
  • Depacon (valproate sodium)
    +
    ibuprofen
    1 interaction

    Monitor/Modify Tx

    valproic acid + ibuprofen

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • ibuprofen lysine
  • Depacon (valproate sodium)
    +
    ibuprofen lysine
    1 interaction

    Monitor/Modify Tx

    valproic acid + ibuprofen lysine

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • icosapent ethyl
  • Depacon (valproate sodium)
    +
    icosapent ethyl
    1 interaction

    Monitor/Modify Tx

    valproic acid + icosapent ethyl

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • idarubicin
  • Depacon (valproate sodium)
    +
    idarubicin
    1 interaction

    Monitor/Modify Tx

    valproic acid + idarubicin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • idecabtagene vicleucel
  • Depacon (valproate sodium)
    +
    idecabtagene vicleucel
    1 interaction

    Monitor/Modify Tx

    valproic acid + idecabtagene vicleucel

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, idecabtagene vicleucel may decr. seizure threshold)

  • idelalisib
  • Depacon (valproate sodium)
    +
    idelalisib
    1 interaction

    Monitor/Modify Tx

    valproic acid + idelalisib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ifosfamide
  • Depacon (valproate sodium)
    +
    ifosfamide
    1 interaction

    Monitor/Modify Tx

    valproic acid + ifosfamide

    monitor CBC; D/C one or both drugs if encephalopathy occurs: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, ifosfamide may decr. seizure threshold)

  • imatinib
  • Depacon (valproate sodium)
    +
    imatinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + imatinib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding (additive effects)

  • imetelstat
  • Depacon (valproate sodium)
    +
    imetelstat
    1 interaction

    Monitor/Modify Tx

    valproic acid + imetelstat

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • indomethacin
  • Depacon (valproate sodium)
    +
    indomethacin
    1 interaction

    Monitor/Modify Tx

    valproic acid + indomethacin

    monitor bleeding s/sx: combo may incr. indomethacin levels, risk of GI or other bleeding (including life-threatening), other adverse effects (UGT inhibited, additive effects)

  • inotuzumab ozogamicin
  • Depacon (valproate sodium)
    +
    inotuzumab ozogamicin
    1 interaction

    Monitor/Modify Tx

    valproic acid + inotuzumab ozogamicin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • interferon beta 1a
  • Depacon (valproate sodium)
    +
    interferon beta 1a
    1 interaction

    Monitor/Modify Tx

    valproic acid + interferon beta 1a

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, interferon beta 1a may decr. seizure threshold)

  • interferon beta 1b
  • Depacon (valproate sodium)
    +
    interferon beta 1b
    1 interaction

    Monitor/Modify Tx

    valproic acid + interferon beta 1b

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, interferon beta 1b may decr. seizure threshold)

  • interferon gamma 1b
  • Depacon (valproate sodium)
    +
    interferon gamma 1b
    1 interaction

    Monitor/Modify Tx

    valproic acid + interferon gamma 1b

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • irinotecan
  • Depacon (valproate sodium)
    +
    irinotecan
    1 interaction

    Monitor/Modify Tx

    valproic acid + irinotecan

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • isatuximab
  • Depacon (valproate sodium)
    +
    isatuximab
    1 interaction

    Monitor/Modify Tx

    valproic acid + isatuximab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • isoflurane
  • Depacon (valproate sodium)
    +
    isoflurane
    1 interaction

    Monitor/Modify Tx

    valproic acid + isoflurane

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • isoniazid
  • Depacon (valproate sodium)
    +
    isoniazid
    1 interaction

    Monitor/Modify Tx

    valproic acid + isoniazid

    monitor valproic acid levels: combo may alter seizure control; may incr. valproic acid levels, risk of adverse effects (antagonistic effects, isoniazid may decr. seizure threshold; mechanism unknown)

  • ivosidenib
  • Depacon (valproate sodium)
    +
    ivosidenib
    1 interaction

    Monitor/Modify Tx

    valproic acid + ivosidenib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ixabepilone
  • Depacon (valproate sodium)
    +
    ixabepilone
    1 interaction

    Monitor/Modify Tx

    valproic acid + ixabepilone

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ketamine
  • Depacon (valproate sodium)
    +
    ketamine
    1 interaction

    Monitor/Modify Tx

    valproic acid + ketamine

    monitor respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression (including life-threatening), psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, ketamine may decr. seizure threshold)

  • ketoprofen
  • Depacon (valproate sodium)
    +
    ketoprofen
    1 interaction

    Monitor/Modify Tx

    valproic acid + ketoprofen

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • ketorolac
  • Depacon (valproate sodium)
    +
    ketorolac
    1 interaction

    Monitor/Modify Tx

    valproic acid + ketorolac

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening; may alter seizure control (additive effects; antagonistic effects, ketorolac may decr. seizure threshold)

  • ketorolac ophthalmic
  • Depacon (valproate sodium)
    +
    ketorolac ophthalmic
    1 interaction

    Monitor/Modify Tx

    valproic acid + ketorolac ophthalmic

    monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

  • lamotrigine
  • Depacon (valproate sodium)
    +
    lamotrigine
    1 interaction

    Monitor/Modify Tx

    valproic acid + lamotrigine

    titrate slowly, refer to Adult or Peds dosing for guidance: combo may incr. lamotrigine levels, risk of CNS depression, psychomotor impairment, serious skin rash (including life-threating), other adverse effects (UGT inhibited, additive effects)

  • leflunomide
  • Depacon (valproate sodium)
    +
    leflunomide
    1 interaction

    Monitor/Modify Tx

    valproic acid + leflunomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lemborexant
  • Depacon (valproate sodium)
    +
    lemborexant
    1 interaction

    Monitor/Modify Tx

    valproic acid + lemborexant

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • lenalidomide
  • Depacon (valproate sodium)
    +
    lenalidomide
    1 interaction

    Monitor/Modify Tx

    valproic acid + lenalidomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lenvatinib
  • Depacon (valproate sodium)
    +
    lenvatinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + lenvatinib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • levomilnacipran
  • Depacon (valproate sodium)
    +
    levomilnacipran
    1 interaction

    Monitor/Modify Tx

    valproic acid + levomilnacipran

    monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, levomilnacipran may decr. seizure threshold)

  • levorphanol
  • Depacon (valproate sodium)
    +
    levorphanol
    1 interaction

    Monitor/Modify Tx

    valproic acid + levorphanol

    monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, levorphanol may decr. seizure threshold)

  • levothyroxine
  • Depacon (valproate sodium)
    +
    levothyroxine
    1 interaction

    Monitor/Modify Tx

    valproic acid + levothyroxine

    monitor thyroid fxn: combo may decr. thyroid hormone levels, efficacy (UGT induced)

  • lifileucel
  • Depacon (valproate sodium)
    +
    lifileucel
    1 interaction

    Monitor/Modify Tx

    valproic acid + lifileucel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

  • linezolid
  • Depacon (valproate sodium)
    +
    linezolid
    1 interaction

    Monitor/Modify Tx

    valproic acid + linezolid

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, linezolid may decr. seizure threshold)

  • linvoseltamab
  • Depacon (valproate sodium)
    +
    linvoseltamab
    1 interaction

    Monitor/Modify Tx

    valproic acid + linvoseltamab

    monitor CBC: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression (additive effects)

  • liothyronine
  • Depacon (valproate sodium)
    +
    liothyronine
    1 interaction

    Monitor/Modify Tx

    valproic acid + liothyronine

    monitor thyroid fxn: combo may decr. thyroid hormone levels, efficacy (UGT induced)

  • lisocabtagene maraleucel
  • Depacon (valproate sodium)
    +
    lisocabtagene maraleucel
    1 interaction

    Monitor/Modify Tx

    valproic acid + lisocabtagene maraleucel

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, lisocabtagene maraleucel may decr. seizure threshold)

  • lomustine
  • Depacon (valproate sodium)
    +
    lomustine
    1 interaction

    Monitor/Modify Tx

    valproic acid + lomustine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lonafarnib
  • Depacon (valproate sodium)
    +
    lonafarnib
    1 interaction

    Monitor/Modify Tx

    valproic acid + lonafarnib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • loncastuximab tesirine
  • Depacon (valproate sodium)
    +
    loncastuximab tesirine
    1 interaction

    Monitor/Modify Tx

    valproic acid + loncastuximab tesirine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lopinavir/ritonavir
  • Depacon (valproate sodium)
    +
    lopinavir/ ritonavir
    1 interaction

    Monitor/Modify Tx

    valproic acid + lopinavir/ ritonavir

    monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

  • lovotibeglogene autotemcel
  • Depacon (valproate sodium)
    +
    lovotibeglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    valproic acid + lovotibeglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • lurbinectedin
  • Depacon (valproate sodium)
    +
    lurbinectedin
    1 interaction

    Monitor/Modify Tx

    valproic acid + lurbinectedin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lutetium Lu 177 dotatate
  • Depacon (valproate sodium)
    +
    lutetium Lu 177 dotatate
    1 interaction

    Monitor/Modify Tx

    valproic acid + lutetium Lu 177 dotatate

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lutetium Lu 177 vipivotide tetraxetan
  • Depacon (valproate sodium)
    +
    lutetium Lu 177 vipivotide tetraxetan
    1 interaction

    Monitor/Modify Tx

    valproic acid + lutetium Lu 177 vipivotide tetraxetan

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lymphocyte immune globulin, anti-thymocyte globulin
  • Depacon (valproate sodium)
    +
    lymphocyte immune globulin, anti-thymocyte globulin
    1 interaction

    Monitor/Modify Tx

    valproic acid + lymphocyte immune globulin, anti-thymocyte globulin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • magnesium salicylate
  • Depacon (valproate sodium)
    +
    magnesium salicylate
    1 interaction

    Monitor/Modify Tx

    valproic acid + magnesium salicylate

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding (additive effects)

  • meclofenamate
  • Depacon (valproate sodium)
    +
    meclofenamate
    1 interaction

    Monitor/Modify Tx

    valproic acid + meclofenamate

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • mefenamic acid
  • Depacon (valproate sodium)
    +
    mefenamic acid
    1 interaction

    Monitor/Modify Tx

    valproic acid + mefenamic acid

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • meloxicam
  • Depacon (valproate sodium)
    +
    meloxicam
    1 interaction

    Monitor/Modify Tx

    valproic acid + meloxicam

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • melphalan
  • Depacon (valproate sodium)
    +
    melphalan
    1 interaction

    Monitor/Modify Tx

    valproic acid + melphalan

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • meperidine
  • Depacon (valproate sodium)
    +
    meperidine
    1 interaction

    Monitor/Modify Tx

    valproic acid + meperidine

    monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, meperidine may decr. seizure threshold)

  • mercaptopurine
  • Depacon (valproate sodium)
    +
    mercaptopurine
    1 interaction

    Monitor/Modify Tx

    valproic acid + mercaptopurine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mesalamine
  • Depacon (valproate sodium)
    +
    mesalamine
    1 interaction

    Monitor/Modify Tx

    valproic acid + mesalamine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mesalamine rectal
  • Depacon (valproate sodium)
    +
    mesalamine rectal
    1 interaction

    Monitor/Modify Tx

    valproic acid + mesalamine rectal

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • methadone
  • Depacon (valproate sodium)
    +
    methadone
    1 interaction

    Monitor/Modify Tx

    valproic acid + methadone

    monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, methadone may decr. seizure threshold)

  • methohexital
  • Depacon (valproate sodium)
    +
    methohexital
    1 interaction

    Monitor/Modify Tx

    valproic acid + methohexital

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • methotrexate
  • Depacon (valproate sodium)
    +
    methotrexate
    1 interaction

    Monitor/Modify Tx

    valproic acid + methotrexate

    monitor CBC, bleeding s/sx, valproic acid levels: combo decr. valproic acid levels, efficacy; may incr. risk of myelosuppression, GI or other bleeding, including life-threatening; may alter seizure control (mechanism unknown; additive effects; antagonistic effects, methotrexate may decr. seizure threshold)

  • methyl salicylate topical
  • Depacon (valproate sodium)
    +
    methyl salicylate topical
    1 interaction

    Monitor/Modify Tx

    valproic acid + methyl salicylate topical

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects, systemic salicylate absorption may occur from topical use)

  • midostaurin
  • Depacon (valproate sodium)
    +
    midostaurin
    1 interaction

    Monitor/Modify Tx

    valproic acid + midostaurin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • milnacipran
  • Depacon (valproate sodium)
    +
    milnacipran
    1 interaction

    Monitor/Modify Tx

    valproic acid + milnacipran

    monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, milnacipran may decr. seizure threshold)

  • mirtazapine
  • Depacon (valproate sodium)
    +
    mirtazapine
    1 interaction

    Monitor/Modify Tx

    valproic acid + mirtazapine

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, mirtazapine may decr. seizure threshold)

  • mitomycin
  • Depacon (valproate sodium)
    +
    mitomycin
    1 interaction

    Monitor/Modify Tx

    valproic acid + mitomycin

    monitor CBC; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of myelosuppression (additive effects)

  • mitotane
  • Depacon (valproate sodium)
    +
    mitotane
    1 interaction

    Monitor/Modify Tx

    valproic acid + mitotane

    monitor CBC, bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, myelosuppression, bleeding (additive effects)

  • mitoxantrone
  • Depacon (valproate sodium)
    +
    mitoxantrone
    1 interaction

    Monitor/Modify Tx

    valproic acid + mitoxantrone

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mogamulizumab
  • Depacon (valproate sodium)
    +
    mogamulizumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + mogamulizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • momelotinib
  • Depacon (valproate sodium)
    +
    momelotinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + momelotinib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • monomethyl fumarate
  • Depacon (valproate sodium)
    +
    monomethyl fumarate
    1 interaction

    Monitor/Modify Tx

    valproic acid + monomethyl fumarate

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • morphine
  • Depacon (valproate sodium)
    +
    morphine
    1 interaction

    Monitor/Modify Tx

    valproic acid + morphine

    monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, morphine may decr. seizure threshold)

  • mosunetuzumab
  • Depacon (valproate sodium)
    +
    mosunetuzumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + mosunetuzumab

    monitor CBC: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment (additive effects)

  • mycophenolate mofetil
  • Depacon (valproate sodium)
    +
    mycophenolate mofetil
    1 interaction

    Monitor/Modify Tx

    valproic acid + mycophenolate mofetil

    monitor CBC, bleeding s/sx, consider monitoring mycophenolic acid levels: combo may incr. mycophenolic acid levels, risk of serious infection, myelosuppression, GI or other bleeding, CNS depression, psychomotor impairment, other adverse effects (UGT inhibited, additive effects)

  • mycophenolic acid
  • Depacon (valproate sodium)
    +
    mycophenolic acid
    1 interaction

    Monitor/Modify Tx

    valproic acid + mycophenolic acid

    monitor CBC, bleeding s/sx: combo may incr. mycophenolic acid levels, risk of serious infection, myelosuppression, GI or other bleeding, other adverse effects (UGT inhibited, additive effects)

  • nabumetone
  • Depacon (valproate sodium)
    +
    nabumetone
    1 interaction

    Monitor/Modify Tx

    valproic acid + nabumetone

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • nalbuphine
  • Depacon (valproate sodium)
    +
    nalbuphine
    1 interaction

    Monitor/Modify Tx

    valproic acid + nalbuphine

    monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, nalbuphine may decr. seizure threshold)

  • naproxen
  • Depacon (valproate sodium)
    +
    naproxen
    1 interaction

    Monitor/Modify Tx

    valproic acid + naproxen

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • nattokinase
  • Depacon (valproate sodium)
    +
    nattokinase
    1 interaction

    Monitor/Modify Tx

    valproic acid + nattokinase

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • nelarabine
  • Depacon (valproate sodium)
    +
    nelarabine
    1 interaction

    Monitor/Modify Tx

    valproic acid + nelarabine

    monitor CBC; withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, nelarabine may decr. seizure threshold)

  • nelfinavir
  • Depacon (valproate sodium)
    +
    nelfinavir
    1 interaction

    Monitor/Modify Tx

    valproic acid + nelfinavir

    monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

  • nepafenac ophthalmic
  • Depacon (valproate sodium)
    +
    nepafenac ophthalmic
    1 interaction

    Monitor/Modify Tx

    valproic acid + nepafenac ophthalmic

    monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

  • nevirapine
  • Depacon (valproate sodium)
    +
    nevirapine
    1 interaction

    Monitor/Modify Tx

    valproic acid + nevirapine

    monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

  • niacin (vitamin B3)
  • Depacon (valproate sodium)
    +
    niacin (vitamin B3)
    1 interaction

    Monitor/Modify Tx

    valproic acid + niacin (vitamin B3)

    monitor platelets, bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • nilotinib
  • Depacon (valproate sodium)
    +
    nilotinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + nilotinib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

  • nintedanib
  • Depacon (valproate sodium)
    +
    nintedanib
    1 interaction

    Monitor/Modify Tx

    valproic acid + nintedanib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • niraparib
  • Depacon (valproate sodium)
    +
    niraparib
    1 interaction

    Monitor/Modify Tx

    valproic acid + niraparib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • nortriptyline
  • Depacon (valproate sodium)
    +
    nortriptyline
    1 interaction

    Monitor/Modify Tx

    valproic acid + nortriptyline

    monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of CNS depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metabolism possibly inhibited, additive effects; antagonistic effects, nortriptyline may decr. seizure threshold)

  • nusinersen
  • Depacon (valproate sodium)
    +
    nusinersen
    1 interaction

    Monitor/Modify Tx

    valproic acid + nusinersen

    monitor platelets, bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • obecabtagene autoleucel
  • Depacon (valproate sodium)
    +
    obecabtagene autoleucel
    1 interaction

    Monitor/Modify Tx

    valproic acid + obecabtagene autoleucel

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, obecabtagene autoleucel may decr. seizure threshold)

  • obinutuzumab
  • Depacon (valproate sodium)
    +
    obinutuzumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + obinutuzumab

    monitor CBC, platelets, bleeding s/sx; consider holding valproic acid, especially during first obinutuzumab cycle: combo may incr. risk of myelosuppression, severe bleeding, including life-threatening (additive effects)

  • ofatumumab
  • Depacon (valproate sodium)
    +
    ofatumumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + ofatumumab

    monitor CBC; myelosuppression risk may be lower w/ ofatumumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

  • olanzapine
  • Depacon (valproate sodium)
    +
    olanzapine
    1 interaction

    Monitor/Modify Tx

    valproic acid + olanzapine

    monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, including orthostasis; may alter seizure control (additive effects; antagonistic effects, olanzapine may decr. seizure threshold)

  • olaparib
  • Depacon (valproate sodium)
    +
    olaparib
    1 interaction

    Monitor/Modify Tx

    valproic acid + olaparib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • oliceridine
  • Depacon (valproate sodium)
    +
    oliceridine
    1 interaction

    Monitor/Modify Tx

    valproic acid + oliceridine

    monitor respiratory rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment, hypotension; may alter seizure control (additive effects; antagonistic effects, oliceridine may decr. seizure threshold)

  • olsalazine
  • Depacon (valproate sodium)
    +
    olsalazine
    1 interaction

    Monitor/Modify Tx

    valproic acid + olsalazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • omega-3-acid
  • Depacon (valproate sodium)
    +
    omega-3-acid
    1 interaction

    Monitor/Modify Tx

    valproic acid + omega-3-acid

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • opicapone
  • Depacon (valproate sodium)
    +
    opicapone
    1 interaction

    Monitor/Modify Tx

    valproic acid + opicapone

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • opium
  • Depacon (valproate sodium)
    +
    opium
    1 interaction

    Monitor/Modify Tx

    valproic acid + opium

    monitor respiratory rate; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, morphine in opium may decr. seizure threshold)

  • oxaliplatin
  • Depacon (valproate sodium)
    +
    oxaliplatin
    1 interaction

    Monitor/Modify Tx

    valproic acid + oxaliplatin

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding (additive effects)

  • oxaprozin
  • Depacon (valproate sodium)
    +
    oxaprozin
    1 interaction

    Monitor/Modify Tx

    valproic acid + oxaprozin

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • oxazepam
  • Depacon (valproate sodium)
    +
    oxazepam
    1 interaction

    Monitor/Modify Tx

    valproic acid + oxazepam

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • oxybutynin
  • Depacon (valproate sodium)
    +
    oxybutynin
    1 interaction

    Monitor/Modify Tx

    valproic acid + oxybutynin

    decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment; somnolence less likely with oxybutynin transdermal patch (additive effects)

  • oxycodone
  • Depacon (valproate sodium)
    +
    oxycodone
    1 interaction

    Monitor/Modify Tx

    valproic acid + oxycodone

    monitor respiratory rate; decr. oxycodone start dose by at least 50%, consider decr. valproic acid dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, oxycodone may decr. seizure threshold)

  • oxymorphone
  • Depacon (valproate sodium)
    +
    oxymorphone
    1 interaction

    Monitor/Modify Tx

    valproic acid + oxymorphone

    monitor respiratory rate; decr. oxymorphone start dose by at least 50%, consider decr. valproic acid dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, oxymorphone may decr. seizure threshold)

  • paclitaxel
  • Depacon (valproate sodium)
    +
    paclitaxel
    1 interaction

    Monitor/Modify Tx

    valproic acid + paclitaxel

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pacritinib
  • Depacon (valproate sodium)
    +
    pacritinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + pacritinib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

  • palbociclib
  • Depacon (valproate sodium)
    +
    palbociclib
    1 interaction

    Monitor/Modify Tx

    valproic acid + palbociclib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • paroxetine
  • Depacon (valproate sodium)
    +
    paroxetine
    1 interaction

    Monitor/Modify Tx

    valproic acid + paroxetine

    monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, paroxetine may decr. seizure threshold)

  • pazopanib
  • Depacon (valproate sodium)
    +
    pazopanib
    1 interaction

    Monitor/Modify Tx

    valproic acid + pazopanib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • pegaspargase
  • Depacon (valproate sodium)
    +
    pegaspargase
    1 interaction

    Monitor/Modify Tx

    valproic acid + pegaspargase

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • peginterferon alfa 2a
  • Depacon (valproate sodium)
    +
    peginterferon alfa 2a
    1 interaction

    Monitor/Modify Tx

    valproic acid + peginterferon alfa 2a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • peginterferon beta 1a
  • Depacon (valproate sodium)
    +
    peginterferon beta 1a
    1 interaction

    Monitor/Modify Tx

    valproic acid + peginterferon beta 1a

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, peginterferon beta 1a may decr. seizure threshold)

  • pemetrexed
  • Depacon (valproate sodium)
    +
    pemetrexed
    1 interaction

    Monitor/Modify Tx

    valproic acid + pemetrexed

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • penicillamine
  • Depacon (valproate sodium)
    +
    penicillamine
    1 interaction

    Monitor/Modify Tx

    valproic acid + penicillamine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • penicillin G
  • Depacon (valproate sodium)
    +
    penicillin G
    1 interaction

    Monitor/Modify Tx

    valproic acid + penicillin G

    monitor bleeding s/sx, especially w/ large penicillin G doses and/or concomitant renal impairment: combo may incr. risk of bleeding; may alter seizure control (additive effects; antagonistic effects, penicillin G may decr. seizure threshold)

  • pentamidine
  • Depacon (valproate sodium)
    +
    pentamidine
    1 interaction

    Monitor/Modify Tx

    valproic acid + pentamidine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pentazocine
  • Depacon (valproate sodium)
    +
    pentazocine
    1 interaction

    Monitor/Modify Tx

    valproic acid + pentazocine

    monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, pentazocine may decr. seizure threshold)

  • pentobarbital
  • Depacon (valproate sodium)
    +
    pentobarbital
    1 interaction

    Monitor/Modify Tx

    valproic acid + pentobarbital

    monitor valproic acid levels, respiratory rate: combo may decr. valproic acid levels, efficacy; may incr. pentobarbital levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (UGT induced; hepatic metabolism possibly inhibited, additive effects)

  • pentosan polysulfate sodium
  • Depacon (valproate sodium)
    +
    pentosan polysulfate sodium
    1 interaction

    Monitor/Modify Tx

    valproic acid + pentosan polysulfate sodium

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • pentostatin
  • Depacon (valproate sodium)
    +
    pentostatin
    1 interaction

    Monitor/Modify Tx

    valproic acid + pentostatin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pentoxifylline
  • Depacon (valproate sodium)
    +
    pentoxifylline
    1 interaction

    Monitor/Modify Tx

    valproic acid + pentoxifylline

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • perphenazine
  • Depacon (valproate sodium)
    +
    perphenazine
    1 interaction

    Monitor/Modify Tx

    valproic acid + perphenazine

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, perphenazine may decr. seizure threshold)

  • phenobarbital
  • Depacon (valproate sodium)
    +
    phenobarbital
    1 interaction

    Monitor/Modify Tx

    valproic acid + phenobarbital

    monitor levels of both drugs, ECG, respiratory rate: combo may incr. phenobarbital levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects; may decr. valproic acid levels, efficacy (hepatic metabolism possibly inhibited, additive effects; hepatic metabolism possibly induced, UGT possibly induced)

  • phenytoin
  • Depacon (valproate sodium)
    +
    phenytoin
    1 interaction

    Monitor/Modify Tx

    valproic acid + phenytoin

    monitor levels of both drugs, ammonia levels: combo may decr. valproic acid levels, efficacy; may incr. or decr. phenytoin levels, incr. risk of toxicity or decr. efficacy; may incr. risk of CNS depression, psychomotor impairment, hyperammonemia (UGT induced; hepatic metabolism altered; additive effects)

  • piperacillin
  • Depacon (valproate sodium)
    +
    piperacillin
    1 interaction

    Monitor/Modify Tx

    valproic acid + piperacillin

    monitor bleeding s/sx, especially w/ prolonged piperacillin tx and/or concomitant renal impairment: combo may incr. risk of bleeding; may alter seizure control (additive effects; antagonistic effects, piperacillin may decr. seizure threshold)

  • piroxicam
  • Depacon (valproate sodium)
    +
    piroxicam
    1 interaction

    Monitor/Modify Tx

    valproic acid + piroxicam

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • pirtobrutinib
  • Depacon (valproate sodium)
    +
    pirtobrutinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + pirtobrutinib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

  • plasminogen, human
  • Depacon (valproate sodium)
    +
    plasminogen, human
    1 interaction

    Monitor/Modify Tx

    valproic acid + plasminogen, human

    monitor bleeding s/sx, especially during and x4h after plasminogen infusion: combo may incr. risk of GI or other bleeding (additive effects)

  • polatuzumab vedotin
  • Depacon (valproate sodium)
    +
    polatuzumab vedotin
    1 interaction

    Monitor/Modify Tx

    valproic acid + polatuzumab vedotin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pomalidomide
  • Depacon (valproate sodium)
    +
    pomalidomide
    1 interaction

    Monitor/Modify Tx

    valproic acid + pomalidomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ponatinib
  • Depacon (valproate sodium)
    +
    ponatinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + ponatinib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

  • porfimer
  • Depacon (valproate sodium)
    +
    porfimer
    1 interaction

    Monitor/Modify Tx

    valproic acid + porfimer

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • pralatrexate
  • Depacon (valproate sodium)
    +
    pralatrexate
    1 interaction

    Monitor/Modify Tx

    valproic acid + pralatrexate

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pralsetinib
  • Depacon (valproate sodium)
    +
    pralsetinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + pralsetinib

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • prasugrel
  • Depacon (valproate sodium)
    +
    prasugrel
    1 interaction

    Monitor/Modify Tx

    valproic acid + prasugrel

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • pregabalin
  • Depacon (valproate sodium)
    +
    pregabalin
    1 interaction

    Monitor/Modify Tx

    valproic acid + pregabalin

    monitor respiratory rate: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

  • primidone
  • Depacon (valproate sodium)
    +
    primidone
    1 interaction

    Monitor/Modify Tx

    valproic acid + primidone

    monitor levels, respiratory rate: combo may decr. valproic acid levels, efficacy; may incr. primidone levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (UGT induced; hepatic metabolism inhibited, additive effects)

  • procarbazine
  • Depacon (valproate sodium)
    +
    procarbazine
    1 interaction

    Monitor/Modify Tx

    valproic acid + procarbazine

    monitor CBC: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, procarbazine may decr. seizure threshold)

  • proguanil
  • Depacon (valproate sodium)
    +
    proguanil
    1 interaction

    Monitor/Modify Tx

    valproic acid + proguanil

    monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

  • propofol
  • Depacon (valproate sodium)
    +
    propofol
    1 interaction

    Monitor/Modify Tx

    valproic acid + propofol

    monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. propofol levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects; may alter seizure control (UGT inhibited, additive effects; antagonistic effects, propofol may decr. seizure threshold)

  • pyrimethamine
  • Depacon (valproate sodium)
    +
    pyrimethamine
    1 interaction

    Monitor/Modify Tx

    valproic acid + pyrimethamine

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, pyrimethamine may decr. seizure threshold)

  • quazepam
  • Depacon (valproate sodium)
    +
    quazepam
    1 interaction

    Monitor/Modify Tx

    valproic acid + quazepam

    monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • quizartinib
  • Depacon (valproate sodium)
    +
    quizartinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + quizartinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ramucirumab
  • Depacon (valproate sodium)
    +
    ramucirumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + ramucirumab

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • ranibizumab
  • Depacon (valproate sodium)
    +
    ranibizumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + ranibizumab

    monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

  • regorafenib
  • Depacon (valproate sodium)
    +
    regorafenib
    1 interaction

    Monitor/Modify Tx

    valproic acid + regorafenib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • remibrutinib
  • Depacon (valproate sodium)
    +
    remibrutinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + remibrutinib

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • remifentanil
  • Depacon (valproate sodium)
    +
    remifentanil
    1 interaction

    Monitor/Modify Tx

    valproic acid + remifentanil

    monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, remifentanil may decr. seizure threshold)

  • remimazolam
  • Depacon (valproate sodium)
    +
    remimazolam
    1 interaction

    Monitor/Modify Tx

    valproic acid + remimazolam

    monitor respiratory rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment (additive effects)

  • resveratrol
  • Depacon (valproate sodium)
    +
    resveratrol
    1 interaction

    Monitor/Modify Tx

    valproic acid + resveratrol

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • reteplase
  • Depacon (valproate sodium)
    +
    reteplase
    1 interaction

    Monitor/Modify Tx

    valproic acid + reteplase

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • revakinagene taroretcel
  • Depacon (valproate sodium)
    +
    revakinagene taroretcel
    1 interaction

    Monitor/Modify Tx

    valproic acid + revakinagene taroretcel

    monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

  • ribavirin
  • Depacon (valproate sodium)
    +
    ribavirin
    1 interaction

    Monitor/Modify Tx

    valproic acid + ribavirin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ribociclib
  • Depacon (valproate sodium)
    +
    ribociclib
    1 interaction

    Monitor/Modify Tx

    valproic acid + ribociclib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • rifabutin
  • Depacon (valproate sodium)
    +
    rifabutin
    1 interaction

    Monitor/Modify Tx

    valproic acid + rifabutin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • rifampin
  • Depacon (valproate sodium)
    +
    rifampin
    1 interaction

    Monitor/Modify Tx

    valproic acid + rifampin

    monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

  • ritonavir
  • Depacon (valproate sodium)
    +
    ritonavir
    1 interaction

    Monitor/Modify Tx

    valproic acid + ritonavir

    monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

  • rituximab
  • Depacon (valproate sodium)
    +
    rituximab
    1 interaction

    Monitor/Modify Tx

    valproic acid + rituximab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • rivaroxaban
  • Depacon (valproate sodium)
    +
    rivaroxaban
    1 interaction

    Monitor/Modify Tx

    valproic acid + rivaroxaban

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • romidepsin
  • Depacon (valproate sodium)
    +
    romidepsin
    1 interaction

    Monitor/Modify Tx

    valproic acid + romidepsin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • rucaparib
  • Depacon (valproate sodium)
    +
    rucaparib
    1 interaction

    Monitor/Modify Tx

    valproic acid + rucaparib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • rufinamide
  • Depacon (valproate sodium)
    +
    rufinamide
    1 interaction

    Monitor/Modify Tx

    valproic acid + rufinamide

    start valproate at low dose in pts on rufinamide; start rufinamide <400 mg/day in adult pts or <10 mg/kg/day in peds pts on valproate: combo may incr. rufinamide levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ruxolitinib
  • Depacon (valproate sodium)
    +
    ruxolitinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + ruxolitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ruxolitinib topical
  • Depacon (valproate sodium)
    +
    ruxolitinib topical
    1 interaction

    Monitor/Modify Tx

    valproic acid + ruxolitinib topical

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • salsalate
  • Depacon (valproate sodium)
    +
    salsalate
    1 interaction

    Monitor/Modify Tx

    valproic acid + salsalate

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • sapropterin
  • Depacon (valproate sodium)
    +
    sapropterin
    1 interaction

    Monitor/Modify Tx

    valproic acid + sapropterin

    monitor Phe levels: combo may decr. sapropterin efficacy (dihydrofolate reductase inhibited)

  • sarilumab
  • Depacon (valproate sodium)
    +
    sarilumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + sarilumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • satralizumab
  • Depacon (valproate sodium)
    +
    satralizumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + satralizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • saw palmetto
  • Depacon (valproate sodium)
    +
    saw palmetto
    1 interaction

    Monitor/Modify Tx

    valproic acid + saw palmetto

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • selinexor
  • Depacon (valproate sodium)
    +
    selinexor
    1 interaction

    Monitor/Modify Tx

    valproic acid + selinexor

    monitor CBC: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment (additive effects)

  • selpercatinib
  • Depacon (valproate sodium)
    +
    selpercatinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + selpercatinib

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • selumetinib
  • Depacon (valproate sodium)
    +
    selumetinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + selumetinib

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects, antiplatelet and anticoagulant effects augmented by vitamin E content in selumetinib capsules)

  • sepiapterin
  • Depacon (valproate sodium)
    +
    sepiapterin
    1 interaction

    Monitor/Modify Tx

    valproic acid + sepiapterin

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • sertraline
  • Depacon (valproate sodium)
    +
    sertraline
    1 interaction

    Monitor/Modify Tx

    valproic acid + sertraline

    monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, sertraline may decr. seizure threshold)

  • sevoflurane
  • Depacon (valproate sodium)
    +
    sevoflurane
    1 interaction

    Monitor/Modify Tx

    valproic acid + sevoflurane

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, sevoflurane may decr. seizure threshold)

  • sirolimus
  • Depacon (valproate sodium)
    +
    sirolimus
    1 interaction

    Monitor/Modify Tx

    valproic acid + sirolimus

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sirolimus albumin-bound
  • Depacon (valproate sodium)
    +
    sirolimus albumin-bound
    1 interaction

    Monitor/Modify Tx

    valproic acid + sirolimus albumin-bound

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

  • sodium phenylacetate
  • Depacon (valproate sodium)
    +
    sodium phenylacetate
    1 interaction

    Monitor/Modify Tx

    valproic acid + sodium phenylacetate

    monitor ammonia levels: combo may decr. sodium phenylacetate efficacy (antagonistic effects)

  • sodium phenylbutyrate
  • Depacon (valproate sodium)
    +
    sodium phenylbutyrate
    1 interaction

    Monitor/Modify Tx

    valproic acid + sodium phenylbutyrate

    monitor ammonia levels: combo may decr. sodium phenylbutyrate efficacy (antagonistic effects)

  • sorafenib
  • Depacon (valproate sodium)
    +
    sorafenib
    1 interaction

    Monitor/Modify Tx

    valproic acid + sorafenib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • sotatercept
  • Depacon (valproate sodium)
    +
    sotatercept
    1 interaction

    Monitor/Modify Tx

    valproic acid + sotatercept

    monitor platelets, bleeding s/sx: combo may incr. risk of bleeding, including severe (additive effects)

  • stiripentol
  • Depacon (valproate sodium)
    +
    stiripentol
    1 interaction

    Monitor/Modify Tx

    valproic acid + stiripentol

    monitor CBC: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment (additive effects)

  • streptozocin
  • Depacon (valproate sodium)
    +
    streptozocin
    1 interaction

    Monitor/Modify Tx

    valproic acid + streptozocin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • succimer
  • Depacon (valproate sodium)
    +
    succimer
    1 interaction

    Monitor/Modify Tx

    valproic acid + succimer

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sufentanil
  • Depacon (valproate sodium)
    +
    sufentanil
    1 interaction

    Monitor/Modify Tx

    valproic acid + sufentanil

    monitor respiratory rate, decr. sufentanil start dose, consider decr. valproic acid dose, use lowest effective doses: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, sufentanil may decr. seizure threshold)

  • sulfasalazine
  • Depacon (valproate sodium)
    +
    sulfasalazine
    1 interaction

    Monitor/Modify Tx

    valproic acid + sulfasalazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sulindac
  • Depacon (valproate sodium)
    +
    sulindac
    1 interaction

    Monitor/Modify Tx

    valproic acid + sulindac

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • sunitinib
  • Depacon (valproate sodium)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + sunitinib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • suvorexant
  • Depacon (valproate sodium)
    +
    suvorexant
    1 interaction

    Monitor/Modify Tx

    valproic acid + suvorexant

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • tafasitamab
  • Depacon (valproate sodium)
    +
    tafasitamab
    1 interaction

    Monitor/Modify Tx

    valproic acid + tafasitamab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tagraxofusp
  • Depacon (valproate sodium)
    +
    tagraxofusp
    1 interaction

    Monitor/Modify Tx

    valproic acid + tagraxofusp

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • talazoparib
  • Depacon (valproate sodium)
    +
    talazoparib
    1 interaction

    Monitor/Modify Tx

    valproic acid + talazoparib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • talquetamab
  • Depacon (valproate sodium)
    +
    talquetamab
    1 interaction

    Monitor/Modify Tx

    valproic acid + talquetamab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tapentadol
  • Depacon (valproate sodium)
    +
    tapentadol
    1 interaction

    Monitor/Modify Tx

    valproic acid + tapentadol

    monitor respiratory rate, BP; decrease dose of one or both drugs, use lowest effective doses and shortest duration of concomitant treatment: combo may increase risk of profound CNS and respiratory depression, psychomotor impairment, severe hypotension, including orthostasis, syncope; may alter seizure control (additive effects; antagonistic effects, tapentadol may decrease seizure threshold)

  • tarlatamab
  • Depacon (valproate sodium)
    +
    tarlatamab
    1 interaction

    Monitor/Modify Tx

    valproic acid + tarlatamab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tazemetostat
  • Depacon (valproate sodium)
    +
    tazemetostat
    1 interaction

    Monitor/Modify Tx

    valproic acid + tazemetostat

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • teclistamab
  • Depacon (valproate sodium)
    +
    teclistamab
    1 interaction

    Monitor/Modify Tx

    valproic acid + teclistamab

    monitor CBC: combo may alter seizure control; may incr. risk of myelosuppression (antagonistic effects, teclistamab may decr. seizure threshold; additive effects)

  • telmisartan
  • Depacon (valproate sodium)
    +
    telmisartan
    1 interaction

    Monitor/Modify Tx

    valproic acid + telmisartan

    monitor valproic acid levels: combo may decr. valproic acid levels, efficacy (UGT induced)

  • temazepam
  • Depacon (valproate sodium)
    +
    temazepam
    1 interaction

    Monitor/Modify Tx

    valproic acid + temazepam

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • temozolomide
  • Depacon (valproate sodium)
    +
    temozolomide
    1 interaction

    Monitor/Modify Tx

    valproic acid + temozolomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • temsirolimus
  • Depacon (valproate sodium)
    +
    temsirolimus
    1 interaction

    Monitor/Modify Tx

    valproic acid + temsirolimus

    monitor CBC, bleeding signs/symptoms: combo may incr. risk of myelosuppression, GI or other bleeding (additive effects)

  • tenecteplase
  • Depacon (valproate sodium)
    +
    tenecteplase
    1 interaction

    Monitor/Modify Tx

    valproic acid + tenecteplase

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • teplizumab
  • Depacon (valproate sodium)
    +
    teplizumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + teplizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • teriflunomide
  • Depacon (valproate sodium)
    +
    teriflunomide
    1 interaction

    Monitor/Modify Tx

    valproic acid + teriflunomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • theophylline
  • Depacon (valproate sodium)
    +
    theophylline
    1 interaction

    Monitor/Modify Tx

    valproic acid + theophylline

    monitor theophylline levels: combo may decr. theophylline levels, efficacy; may alter seizure control (hepatic metabolism induced; antagonistic effects, theophylline may decr. seizure threshold)

  • thioguanine
  • Depacon (valproate sodium)
    +
    thioguanine
    1 interaction

    Monitor/Modify Tx

    valproic acid + thioguanine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • thioridazine
  • Depacon (valproate sodium)
    +
    thioridazine
    1 interaction

    Monitor/Modify Tx

    valproic acid + thioridazine

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thioridazine may decr. seizure threshold)

  • thiotepa
  • Depacon (valproate sodium)
    +
    thiotepa
    1 interaction

    Monitor/Modify Tx

    valproic acid + thiotepa

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thiotepa may decr. seizure threshold)

  • thiothixene
  • Depacon (valproate sodium)
    +
    thiothixene
    1 interaction

    Monitor/Modify Tx

    valproic acid + thiothixene

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, thiothixene may decr. seizure threshold)

  • thyroid
  • Depacon (valproate sodium)
    +
    thyroid
    1 interaction

    Monitor/Modify Tx

    valproic acid + thyroid

    monitor thyroid fxn: combo may decr. thyroid hormone levels, efficacy (UGT induced)

  • ticagrelor
  • Depacon (valproate sodium)
    +
    ticagrelor
    1 interaction

    Monitor/Modify Tx

    valproic acid + ticagrelor

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • tipranavir
  • Depacon (valproate sodium)
    +
    tipranavir
    1 interaction

    Monitor/Modify Tx

    valproic acid + tipranavir

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening; may decr. valproic acid levels, efficacy (additive effects; mechanism unknown)

  • tirofiban
  • Depacon (valproate sodium)
    +
    tirofiban
    1 interaction

    Monitor/Modify Tx

    valproic acid + tirofiban

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • tisagenlecleucel
  • Depacon (valproate sodium)
    +
    tisagenlecleucel
    1 interaction

    Monitor/Modify Tx

    valproic acid + tisagenlecleucel

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, tisagenlecleucel may decr. seizure threshold)

  • tisotumab vedotin
  • Depacon (valproate sodium)
    +
    tisotumab vedotin
    1 interaction

    Monitor/Modify Tx

    valproic acid + tisotumab vedotin

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • tivozanib
  • Depacon (valproate sodium)
    +
    tivozanib
    1 interaction

    Monitor/Modify Tx

    valproic acid + tivozanib

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • tocilizumab
  • Depacon (valproate sodium)
    +
    tocilizumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + tocilizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tofacitinib
  • Depacon (valproate sodium)
    +
    tofacitinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + tofacitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tolmetin
  • Depacon (valproate sodium)
    +
    tolmetin
    1 interaction

    Monitor/Modify Tx

    valproic acid + tolmetin

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • topotecan
  • Depacon (valproate sodium)
    +
    topotecan
    1 interaction

    Monitor/Modify Tx

    valproic acid + topotecan

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tovorafenib
  • Depacon (valproate sodium)
    +
    tovorafenib
    1 interaction

    Monitor/Modify Tx

    valproic acid + tovorafenib

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • trabectedin
  • Depacon (valproate sodium)
    +
    trabectedin
    1 interaction

    Monitor/Modify Tx

    valproic acid + trabectedin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tramadol
  • Depacon (valproate sodium)
    +
    tramadol
    1 interaction

    Monitor/Modify Tx

    valproic acid + tramadol

    monitor respiratory rate, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and respiratory depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, tramadol may decr. seizure threshold)

  • trametinib
  • Depacon (valproate sodium)
    +
    trametinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + trametinib

    monitor bleeding s/sx, especially w/ concomitant dabrafenib use: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects)

  • trastuzumab
  • Depacon (valproate sodium)
    +
    trastuzumab
    1 interaction

    Monitor/Modify Tx

    valproic acid + trastuzumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • trazodone
  • Depacon (valproate sodium)
    +
    trazodone
    1 interaction

    Monitor/Modify Tx

    valproic acid + trazodone

    monitor bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

  • treosulfan
  • Depacon (valproate sodium)
    +
    treosulfan
    1 interaction

    Monitor/Modify Tx

    valproic acid + treosulfan

    monitor CBC: combo may incr. risk of myelosuppression; may alter seizure control (additive effects; antagonistic effects, treosulfan may decr. seizure threshold)

  • treprostinil
  • Depacon (valproate sodium)
    +
    treprostinil
    1 interaction

    Monitor/Modify Tx

    valproic acid + treprostinil

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • triazolam
  • Depacon (valproate sodium)
    +
    triazolam
    1 interaction

    Monitor/Modify Tx

    valproic acid + triazolam

    monitor respiratory rate: combo may incr. risk of CNS and respiratory depression, psychomotor impairment (additive effects)

  • trifluridine
  • Depacon (valproate sodium)
    +
    trifluridine
    1 interaction

    Monitor/Modify Tx

    valproic acid + trifluridine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • trimethoprim
  • Depacon (valproate sodium)
    +
    trimethoprim
    1 interaction

    Monitor/Modify Tx

    valproic acid + trimethoprim

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • upadacitinib
  • Depacon (valproate sodium)
    +
    upadacitinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + upadacitinib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding (additive effects)

  • vadadustat
  • Depacon (valproate sodium)
    +
    vadadustat
    1 interaction

    Monitor/Modify Tx

    valproic acid + vadadustat

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding; may alter seizure control (additive effects; antagonistic effects, vadadustat may decr. seizure threshold)

  • vancomycin
  • Depacon (valproate sodium)
    +
    vancomycin
    1 interaction

    Monitor/Modify Tx

    valproic acid + vancomycin

    VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

  • vandetanib
  • Depacon (valproate sodium)
    +
    vandetanib
    1 interaction

    Monitor/Modify Tx

    valproic acid + vandetanib

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • venetoclax
  • Depacon (valproate sodium)
    +
    venetoclax
    1 interaction

    Monitor/Modify Tx

    valproic acid + venetoclax

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • venlafaxine
  • Depacon (valproate sodium)
    +
    venlafaxine
    1 interaction

    Monitor/Modify Tx

    valproic acid + venlafaxine

    monitor bleeding s/sx: combo may incr. risk of bleeding (including life-threatening), CNS depression, psychomotor impairment; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, venlafaxine may decr. seizure threshold)

  • vilazodone
  • Depacon (valproate sodium)
    +
    vilazodone
    1 interaction

    Monitor/Modify Tx

    valproic acid + vilazodone

    monitor bleeding s/sx: combo may incr. risk of CNS depression, psychomotor impairment, bleeding, including life-threatening; may alter seizure control (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake; antagonistic effects, vilazodone may decr. seizure threshold)

  • vinblastine
  • Depacon (valproate sodium)
    +
    vinblastine
    1 interaction

    Monitor/Modify Tx

    valproic acid + vinblastine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • vincristine
  • Depacon (valproate sodium)
    +
    vincristine
    1 interaction

    Monitor/Modify Tx

    valproic acid + vincristine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • vinorelbine
  • Depacon (valproate sodium)
    +
    vinorelbine
    1 interaction

    Monitor/Modify Tx

    valproic acid + vinorelbine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • vinpocetine
  • Depacon (valproate sodium)
    +
    vinpocetine
    1 interaction

    Monitor/Modify Tx

    valproic acid + vinpocetine

    monitor bleeding s/sx: combo may incr. risk of bleeding (additive effects)

  • vorapaxar
  • Depacon (valproate sodium)
    +
    vorapaxar
    1 interaction

    Monitor/Modify Tx

    valproic acid + vorapaxar

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects)

  • vorinostat
  • Depacon (valproate sodium)
    +
    vorinostat
    1 interaction

    Monitor/Modify Tx

    valproic acid + vorinostat

    monitor platelets: combo may incr. risk of severe thrombocytopenia, bleeding (additive effects)

  • vortioxetine
  • Depacon (valproate sodium)
    +
    vortioxetine
    1 interaction

    Monitor/Modify Tx

    valproic acid + vortioxetine

    monitor bleeding s/sx: combo may incr. risk of bleeding, including life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

  • warfarin
  • Depacon (valproate sodium)
    +
    warfarin
    1 interaction

    Monitor/Modify Tx

    valproic acid + warfarin

    monitor INR, bleeding s/sx: combo may decr. warfarin levels, efficacy; may incr. risk of bleeding, including life-threatening (hepatic metabolism induced; synergistic effects)

  • willow bark
  • Depacon (valproate sodium)
    +
    willow bark
    1 interaction

    Monitor/Modify Tx

    valproic acid + willow bark

    monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, including life-threatening (additive effects, willow bark may contain salicylates)

  • zaleplon
  • Depacon (valproate sodium)
    +
    zaleplon
    1 interaction

    Monitor/Modify Tx

    valproic acid + zaleplon

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • zanubrutinib
  • Depacon (valproate sodium)
    +
    zanubrutinib
    1 interaction

    Monitor/Modify Tx

    valproic acid + zanubrutinib

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding, including life-threatening (additive effects)

  • ziconotide
  • Depacon (valproate sodium)
    +
    ziconotide
    1 interaction

    Monitor/Modify Tx

    valproic acid + ziconotide

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • zidovudine
  • Depacon (valproate sodium)
    +
    zidovudine
    1 interaction

    Monitor/Modify Tx

    valproic acid + zidovudine

    monitor CBC: combo may increase zidovudine levels, risk of myelosuppression, other adverse effects (UGT inhibited, additive effects)

  • ziv-aflibercept
  • Depacon (valproate sodium)
    +
    ziv-aflibercept
    1 interaction

    Monitor/Modify Tx

    valproic acid + ziv-aflibercept

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, including life-threatening (additive effects)

  • zolpidem
  • Depacon (valproate sodium)
    +
    zolpidem
    1 interaction

    Monitor/Modify Tx

    valproic acid + zolpidem

    consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Caution Advised

  • 5-HTP
  • Depacon (valproate sodium)
    +
    5-HTP
    1 interaction

    Caution Advised

    valproic acid + 5-HTP

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • acyclovir
  • Depacon (valproate sodium)
    +
    acyclovir
    1 interaction

    Caution Advised

    valproic acid + acyclovir

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, acyclovir may decr. seizure threshold)

  • almotriptan
  • Depacon (valproate sodium)
    +
    almotriptan
    1 interaction

    Caution Advised

    valproic acid + almotriptan

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • amantadine
  • Depacon (valproate sodium)
    +
    amantadine
    1 interaction

    Caution Advised

    valproic acid + amantadine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • amoxapine
  • Depacon (valproate sodium)
    +
    amoxapine
    1 interaction

    Caution Advised

    valproic acid + amoxapine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, amoxapine may decr. seizure threshold)

  • amoxicillin
  • Depacon (valproate sodium)
    +
    amoxicillin
    1 interaction

    Caution Advised

    valproic acid + amoxicillin

    caution advised if seizure disorder use, especially w/ high amoxicillin doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, amoxicillin may decr. seizure threshold)

  • amphetamine
  • Depacon (valproate sodium)
    +
    amphetamine
    1 interaction

    Caution Advised

    valproic acid + amphetamine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, amphetamine may decr. seizure threshold)

  • ampicillin
  • Depacon (valproate sodium)
    +
    ampicillin
    1 interaction

    Caution Advised

    valproic acid + ampicillin

    caution advised if seizure disorder use, especially w/ high ampicillin doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, ampicillin may decr. seizure threshold)

  • apalutamide
  • Depacon (valproate sodium)
    +
    apalutamide
    1 interaction

    Caution Advised

    valproic acid + apalutamide

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, apalutamide may decr. seizure threshold)

  • apomorphine
  • Depacon (valproate sodium)
    +
    apomorphine
    1 interaction

    Caution Advised

    valproic acid + apomorphine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • apraclonidine ophthalmic
  • Depacon (valproate sodium)
    +
    apraclonidine ophthalmic
    1 interaction

    Caution Advised

    valproic acid + apraclonidine ophthalmic

    caution advised if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • aripiprazole bimonthly injection
  • Depacon (valproate sodium)
    +
    aripiprazole bimonthly injection
    1 interaction

    Caution Advised

    valproic acid + aripiprazole bimonthly injection

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

  • aripiprazole lauroxil
  • Depacon (valproate sodium)
    +
    aripiprazole lauroxil
    1 interaction

    Caution Advised

    valproic acid + aripiprazole lauroxil

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

  • aripiprazole monthly injection
  • Depacon (valproate sodium)
    +
    aripiprazole monthly injection
    1 interaction

    Caution Advised

    valproic acid + aripiprazole monthly injection

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

  • aripiprazole oral
  • Depacon (valproate sodium)
    +
    aripiprazole oral
    1 interaction

    Caution Advised

    valproic acid + aripiprazole oral

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, aripiprazole may decr. seizure threshold)

  • artesunate
  • Depacon (valproate sodium)
    +
    artesunate
    1 interaction

    Caution Advised

    valproic acid + artesunate

    caution advised: combo may incr. dihydroartemisinin levels, risk of adverse effects (UGT inhibited; artesunate converted to dihydroartemisinin by esterases)

  • asenapine
  • Depacon (valproate sodium)
    +
    asenapine
    1 interaction

    Caution Advised

    valproic acid + asenapine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, asenapine may decr. seizure threshold)

  • baclofen
  • Depacon (valproate sodium)
    +
    baclofen
    1 interaction

    Caution Advised

    valproic acid + baclofen

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, baclofen may decr. seizure threshold)

  • bazedoxifene
  • Depacon (valproate sodium)
    +
    bazedoxifene
    1 interaction

    Caution Advised

    valproic acid + bazedoxifene

    caution advised: combo may decr. bazedoxifene levels, efficacy (UGT induced)

  • benzphetamine
  • Depacon (valproate sodium)
    +
    benzphetamine
    1 interaction

    Caution Advised

    valproic acid + benzphetamine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, benzphetamine may decr. seizure threshold)

  • betamethasone
  • Depacon (valproate sodium)
    +
    betamethasone
    1 interaction

    Caution Advised

    valproic acid + betamethasone

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, betamethasone may decr. seizure threshold)

  • bictegravir
  • Depacon (valproate sodium)
    +
    bictegravir
    1 interaction

    Caution Advised

    valproic acid + bictegravir

    caution advised if also combined w/ CYP3A4 inducer: combo may decr. bictegravir levels, efficacy (UGT induced)

  • brexpiprazole
  • Depacon (valproate sodium)
    +
    brexpiprazole
    1 interaction

    Caution Advised

    valproic acid + brexpiprazole

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, brexpiprazole may decr. seizure threshold)

  • brimonidine ophthalmic
  • Depacon (valproate sodium)
    +
    brimonidine ophthalmic
    1 interaction

    Caution Advised

    valproic acid + brimonidine ophthalmic

    caution advised if elevated IOP or presbyopia use; OTC ocular redness use OK: combo may increase risk of CNS depression, psychomotor impairment (additive effects)

  • brimonidine topical
  • Depacon (valproate sodium)
    +
    brimonidine topical
    1 interaction

    Caution Advised

    valproic acid + brimonidine topical

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • brivaracetam
  • Depacon (valproate sodium)
    +
    brivaracetam
    1 interaction

    Caution Advised

    valproic acid + brivaracetam

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • bromocriptine
  • Depacon (valproate sodium)
    +
    bromocriptine
    1 interaction

    Caution Advised

    valproic acid + bromocriptine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • brompheniramine
  • Depacon (valproate sodium)
    +
    brompheniramine
    1 interaction

    Caution Advised

    valproic acid + brompheniramine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • buspirone
  • Depacon (valproate sodium)
    +
    buspirone
    1 interaction

    Caution Advised

    valproic acid + buspirone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • cannabis
  • Depacon (valproate sodium)
    +
    cannabis
    1 interaction

    Caution Advised

    valproic acid + cannabis

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cannabis may decr. seizure threshold)

  • carbinoxamine
  • Depacon (valproate sodium)
    +
    carbinoxamine
    1 interaction

    Caution Advised

    valproic acid + carbinoxamine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • cariprazine
  • Depacon (valproate sodium)
    +
    cariprazine
    1 interaction

    Caution Advised

    valproic acid + cariprazine

    caution advised: combo may alter seizure control; may incr. risk of CNS depression, psychomotor impairment (antagonistic effects, cariprazine may decr. seizure threshold; additive effects)

  • carisoprodol
  • Depacon (valproate sodium)
    +
    carisoprodol
    1 interaction

    Caution Advised

    valproic acid + carisoprodol

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • cefazolin
  • Depacon (valproate sodium)
    +
    cefazolin
    1 interaction

    Caution Advised

    valproic acid + cefazolin

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cefazolin may decr. seizure threshold)

  • cefepime
  • Depacon (valproate sodium)
    +
    cefepime
    1 interaction

    Caution Advised

    valproic acid + cefepime

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cefepime may decr. seizure threshold)

  • cefiderocol
  • Depacon (valproate sodium)
    +
    cefiderocol
    1 interaction

    Caution Advised

    valproic acid + cefiderocol

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cefiderocol may decr. seizure threshold)

  • ceftaroline
  • Depacon (valproate sodium)
    +
    ceftaroline
    1 interaction

    Caution Advised

    valproic acid + ceftaroline

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ceftaroline may decr. seizure threshold)

  • ceftazidime
  • Depacon (valproate sodium)
    +
    ceftazidime
    1 interaction

    Caution Advised

    valproic acid + ceftazidime

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ceftazidime may decr. seizure threshold)

  • ceftobiprole
  • Depacon (valproate sodium)
    +
    ceftobiprole
    1 interaction

    Caution Advised

    valproic acid + ceftobiprole

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ceftobiprole may decr. seizure threshold)

  • cenobamate
  • Depacon (valproate sodium)
    +
    cenobamate
    1 interaction

    Caution Advised

    valproic acid + cenobamate

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • cetirizine
  • Depacon (valproate sodium)
    +
    cetirizine
    1 interaction

    Caution Advised

    valproic acid + cetirizine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • chamomile, German
  • Depacon (valproate sodium)
    +
    chamomile, German
    1 interaction

    Caution Advised

    valproic acid + chamomile, German

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • chlophedianol
  • Depacon (valproate sodium)
    +
    chlophedianol
    1 interaction

    Caution Advised

    valproic acid + chlophedianol

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • chlorcyclizine
  • Depacon (valproate sodium)
    +
    chlorcyclizine
    1 interaction

    Caution Advised

    valproic acid + chlorcyclizine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • chloroquine
  • Depacon (valproate sodium)
    +
    chloroquine
    1 interaction

    Caution Advised

    valproic acid + chloroquine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, chloroquine may decr. seizure threshold)

  • chlorpheniramine
  • Depacon (valproate sodium)
    +
    chlorpheniramine
    1 interaction

    Caution Advised

    valproic acid + chlorpheniramine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • chlorzoxazone
  • Depacon (valproate sodium)
    +
    chlorzoxazone
    1 interaction

    Caution Advised

    valproic acid + chlorzoxazone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • ciprofloxacin
  • Depacon (valproate sodium)
    +
    ciprofloxacin
    1 interaction

    Caution Advised

    valproic acid + ciprofloxacin

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ciprofloxacin may decr. seizure threshold)

  • cisatracurium
  • Depacon (valproate sodium)
    +
    cisatracurium
    1 interaction

    Caution Advised

    valproic acid + cisatracurium

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cisatracurium active metabolite may decr. seizure threshold)

  • clemastine
  • Depacon (valproate sodium)
    +
    clemastine
    1 interaction

    Caution Advised

    valproic acid + clemastine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • clomipramine
  • Depacon (valproate sodium)
    +
    clomipramine
    1 interaction

    Caution Advised

    valproic acid + clomipramine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, clomipramine may decr. seizure threshold)

  • cocaine
  • Depacon (valproate sodium)
    +
    cocaine
    1 interaction

    Caution Advised

    valproic acid + cocaine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cocaine may decr. seizure threshold)

  • cortisone
  • Depacon (valproate sodium)
    +
    cortisone
    1 interaction

    Caution Advised

    valproic acid + cortisone

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cortisone may decr. seizure threshold)

  • cyclobenzaprine
  • Depacon (valproate sodium)
    +
    cyclobenzaprine
    1 interaction

    Caution Advised

    valproic acid + cyclobenzaprine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, cyclobenzaprine may decr. seizure threshold)

  • cycloserine
  • Depacon (valproate sodium)
    +
    cycloserine
    1 interaction

    Caution Advised

    valproic acid + cycloserine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cycloserine may decr. seizure threshold)

  • cyclosporine
  • Depacon (valproate sodium)
    +
    cyclosporine
    1 interaction

    Caution Advised

    valproic acid + cyclosporine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, cyclosporine may decr. seizure threshold)

  • cyproheptadine
  • Depacon (valproate sodium)
    +
    cyproheptadine
    1 interaction

    Caution Advised

    valproic acid + cyproheptadine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • dantrolene
  • Depacon (valproate sodium)
    +
    dantrolene
    1 interaction

    Caution Advised

    valproic acid + dantrolene

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • darbepoetin alfa
  • Depacon (valproate sodium)
    +
    darbepoetin alfa
    1 interaction

    Caution Advised

    valproic acid + darbepoetin alfa

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darbepoetin alfa may decr. seizure threshold)

  • darifenacin
  • Depacon (valproate sodium)
    +
    darifenacin
    1 interaction

    Caution Advised

    valproic acid + darifenacin

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • darolutamide
  • Depacon (valproate sodium)
    +
    darolutamide
    1 interaction

    Caution Advised

    valproic acid + darolutamide

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

  • deflazacort
  • Depacon (valproate sodium)
    +
    deflazacort
    1 interaction

    Caution Advised

    valproic acid + deflazacort

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, deflazacort may decr. seizure threshold)

  • delafloxacin
  • Depacon (valproate sodium)
    +
    delafloxacin
    1 interaction

    Caution Advised

    valproic acid + delafloxacin

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, delafloxacin may decr. seizure threshold)

  • desipramine
  • Depacon (valproate sodium)
    +
    desipramine
    1 interaction

    Caution Advised

    valproic acid + desipramine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, desipramine may decr. seizure threshold)

  • deutetrabenazine
  • Depacon (valproate sodium)
    +
    deutetrabenazine
    1 interaction

    Caution Advised

    valproic acid + deutetrabenazine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • dexamethasone
  • Depacon (valproate sodium)
    +
    dexamethasone
    1 interaction

    Caution Advised

    valproic acid + dexamethasone

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, dexamethasone may decr. seizure threshold)

  • dexbrompheniramine
  • Depacon (valproate sodium)
    +
    dexbrompheniramine
    1 interaction

    Caution Advised

    valproic acid + dexbrompheniramine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • dexchlorpheniramine
  • Depacon (valproate sodium)
    +
    dexchlorpheniramine
    1 interaction

    Caution Advised

    valproic acid + dexchlorpheniramine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • dexmethylphenidate
  • Depacon (valproate sodium)
    +
    dexmethylphenidate
    1 interaction

    Caution Advised

    valproic acid + dexmethylphenidate

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, (ser)dexmethylphenidate may decr. seizure threshold)

  • dextroamphetamine
  • Depacon (valproate sodium)
    +
    dextroamphetamine
    1 interaction

    Caution Advised

    valproic acid + dextroamphetamine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, dextroamphetamine may decr. seizure threshold)

  • dichlorphenamide
  • Depacon (valproate sodium)
    +
    dichlorphenamide
    1 interaction

    Caution Advised

    valproic acid + dichlorphenamide

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • dicloxacillin
  • Depacon (valproate sodium)
    +
    dicloxacillin
    1 interaction

    Caution Advised

    valproic acid + dicloxacillin

    caution advised if seizure disorder use, especially w/ high dicloxacillin doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, dicloxacillin may decr. seizure threshold)

  • diethylpropion
  • Depacon (valproate sodium)
    +
    diethylpropion
    1 interaction

    Caution Advised

    valproic acid + diethylpropion

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, diethylpropion may decr. seizure threshold)

  • difelikefalin
  • Depacon (valproate sodium)
    +
    difelikefalin
    1 interaction

    Caution Advised

    valproic acid + difelikefalin

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • difenoxin
  • Depacon (valproate sodium)
    +
    difenoxin
    1 interaction

    Caution Advised

    valproic acid + difenoxin

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • dimenhydrinate
  • Depacon (valproate sodium)
    +
    dimenhydrinate
    1 interaction

    Caution Advised

    valproic acid + dimenhydrinate

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • diphenhydramine
  • Depacon (valproate sodium)
    +
    diphenhydramine
    1 interaction

    Caution Advised

    valproic acid + diphenhydramine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • diphenoxylate
  • Depacon (valproate sodium)
    +
    diphenoxylate
    1 interaction

    Caution Advised

    valproic acid + diphenoxylate

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • domperidone
  • Depacon (valproate sodium)
    +
    domperidone
    1 interaction

    Caution Advised

    valproic acid + domperidone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • donepezil
  • Depacon (valproate sodium)
    +
    donepezil
    1 interaction

    Caution Advised

    valproic acid + donepezil

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, donepezil may decr. seizure threshold)

  • doxepin
  • Depacon (valproate sodium)
    +
    doxepin
    1 interaction

    Caution Advised

    valproic acid + doxepin

    caution advised if seizure disorder use: combo may incr. doxepin levels, risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, doxepin may decr. seizure threshold)

  • doxepin topical
  • Depacon (valproate sodium)
    +
    doxepin topical
    1 interaction

    Caution Advised

    valproic acid + doxepin topical

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • dronabinol
  • Depacon (valproate sodium)
    +
    dronabinol
    1 interaction

    Caution Advised

    valproic acid + dronabinol

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, dronabinol may decr. seizure threshold)

  • efavirenz
  • Depacon (valproate sodium)
    +
    efavirenz
    1 interaction

    Caution Advised

    valproic acid + efavirenz

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • eletriptan
  • Depacon (valproate sodium)
    +
    eletriptan
    1 interaction

    Caution Advised

    valproic acid + eletriptan

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • elinzanetant
  • Depacon (valproate sodium)
    +
    elinzanetant
    1 interaction

    Caution Advised

    valproic acid + elinzanetant

    caution advised if seizure disorder use: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, elinzanetant may decr. seizure threshold)

  • entacapone
  • Depacon (valproate sodium)
    +
    entacapone
    1 interaction

    Caution Advised

    valproic acid + entacapone

    caution advised: combo may incr. entacapone levels, risk of CNS depression, psychomotor impairment, other adverse effects (UGT inhibited, additive effects)

  • enzalutamide
  • Depacon (valproate sodium)
    +
    enzalutamide
    1 interaction

    Caution Advised

    valproic acid + enzalutamide

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, enzalutamide may decr. seizure threshold)

  • ephedra
  • Depacon (valproate sodium)
    +
    ephedra
    1 interaction

    Caution Advised

    valproic acid + ephedra

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ephedra may decr. seizure threshold)

  • epoetin alfa
  • Depacon (valproate sodium)
    +
    epoetin alfa
    1 interaction

    Caution Advised

    valproic acid + epoetin alfa

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, epoetin alfa may decr. seizure threshold)

  • eslicarbazepine acetate
  • Depacon (valproate sodium)
    +
    eslicarbazepine acetate
    1 interaction

    Caution Advised

    valproic acid + eslicarbazepine acetate

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • fenfluramine
  • Depacon (valproate sodium)
    +
    fenfluramine
    1 interaction

    Caution Advised

    valproic acid + fenfluramine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • fesoterodine
  • Depacon (valproate sodium)
    +
    fesoterodine
    1 interaction

    Caution Advised

    valproic acid + fesoterodine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • flibanserin
  • Depacon (valproate sodium)
    +
    flibanserin
    1 interaction

    Caution Advised

    valproic acid + flibanserin

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • foslevodopa
  • Depacon (valproate sodium)
    +
    foslevodopa
    1 interaction

    Caution Advised

    valproic acid + foslevodopa

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • frovatriptan
  • Depacon (valproate sodium)
    +
    frovatriptan
    1 interaction

    Caution Advised

    valproic acid + frovatriptan

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • galantamine
  • Depacon (valproate sodium)
    +
    galantamine
    1 interaction

    Caution Advised

    valproic acid + galantamine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, galantamine may decr. seizure threshold)

  • glycopyrrolate
  • Depacon (valproate sodium)
    +
    glycopyrrolate
    1 interaction

    Caution Advised

    valproic acid + glycopyrrolate

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • goserelin
  • Depacon (valproate sodium)
    +
    goserelin
    1 interaction

    Caution Advised

    valproic acid + goserelin

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, goserelin may decr. seizure threshold)

  • guanfacine
  • Depacon (valproate sodium)
    +
    guanfacine
    1 interaction

    Caution Advised

    valproic acid + guanfacine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • histrelin
  • Depacon (valproate sodium)
    +
    histrelin
    1 interaction

    Caution Advised

    valproic acid + histrelin

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, histrelin may decr. seizure threshold)

  • hyoscyamine
  • Depacon (valproate sodium)
    +
    hyoscyamine
    1 interaction

    Caution Advised

    valproic acid + hyoscyamine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • iloperidone
  • Depacon (valproate sodium)
    +
    iloperidone
    1 interaction

    Caution Advised

    valproic acid + iloperidone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, iloperidone may decr. seizure threshold)

  • imipramine
  • Depacon (valproate sodium)
    +
    imipramine
    1 interaction

    Caution Advised

    valproic acid + imipramine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects; imipramine may decr. seizure threshold)

  • iohexol
  • Depacon (valproate sodium)
    +
    iohexol
    1 interaction

    Caution Advised

    valproic acid + iohexol

    if seizure disorder use, caution advised w/ intrathecal iohexol: combo may alter seizure control (antagonistic effects, intrathecal iohexol may decr. seizure threshold)

  • iopamidol
  • Depacon (valproate sodium)
    +
    iopamidol
    1 interaction

    Caution Advised

    valproic acid + iopamidol

    caution advised w/ intrathecal iopamidol if seizure disorder use: combo may alter seizure control (antagonistic effects, intrathecal iopamidol may decr. seizure threshold)

  • lacosamide
  • Depacon (valproate sodium)
    +
    lacosamide
    1 interaction

    Caution Advised

    valproic acid + lacosamide

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • lenacapavir
  • Depacon (valproate sodium)
    +
    lenacapavir
    1 interaction

    Caution Advised

    valproic acid + lenacapavir

    caution advised: combo may decr. lenacapavir levels, efficacy (UGT induced)

  • leuprolide
  • Depacon (valproate sodium)
    +
    leuprolide
    1 interaction

    Caution Advised

    valproic acid + leuprolide

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

  • levetiracetam
  • Depacon (valproate sodium)
    +
    levetiracetam
    1 interaction

    Caution Advised

    valproic acid + levetiracetam

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • levocarnitine
  • Depacon (valproate sodium)
    +
    levocarnitine
    1 interaction

    Caution Advised

    valproic acid + levocarnitine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, levocarnitine may decr. seizure threshold)

  • levocetirizine
  • Depacon (valproate sodium)
    +
    levocetirizine
    1 interaction

    Caution Advised

    valproic acid + levocetirizine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • levodopa
  • Depacon (valproate sodium)
    +
    levodopa
    1 interaction

    Caution Advised

    valproic acid + levodopa

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • levofloxacin
  • Depacon (valproate sodium)
    +
    levofloxacin
    1 interaction

    Caution Advised

    valproic acid + levofloxacin

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, levofloxacin may decr. seizure threshold)

  • lidocaine
  • Depacon (valproate sodium)
    +
    lidocaine
    1 interaction

    Caution Advised

    valproic acid + lidocaine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, lidocaine may decr. seizure threshold)

  • lidocaine topical
  • Depacon (valproate sodium)
    +
    lidocaine topical
    1 interaction

    Caution Advised

    valproic acid + lidocaine topical

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, lidocaine may decr. seizure threshold)

  • lisdexamfetamine
  • Depacon (valproate sodium)
    +
    lisdexamfetamine
    1 interaction

    Caution Advised

    valproic acid + lisdexamfetamine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, dextroamphetamine may decr. seizure threshold)

  • lithium
  • Depacon (valproate sodium)
    +
    lithium
    1 interaction

    Caution Advised

    valproic acid + lithium

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, lithium may decr. seizure threshold)

  • lofexidine
  • Depacon (valproate sodium)
    +
    lofexidine
    1 interaction

    Caution Advised

    valproic acid + lofexidine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • lorlatinib
  • Depacon (valproate sodium)
    +
    lorlatinib
    1 interaction

    Caution Advised

    valproic acid + lorlatinib

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, lorlatinib may decr. seizure threshold)

  • loxapine
  • Depacon (valproate sodium)
    +
    loxapine
    1 interaction

    Caution Advised

    valproic acid + loxapine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, loxapine may decr. seizure threshold)

  • lumateperone
  • Depacon (valproate sodium)
    +
    lumateperone
    1 interaction

    Caution Advised

    valproic acid + lumateperone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, lumateperone may decr. seizure threshold)

  • lurasidone
  • Depacon (valproate sodium)
    +
    lurasidone
    1 interaction

    Caution Advised

    valproic acid + lurasidone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, lurasidone may decr. seizure threshold)

  • magnesium citrate
  • Depacon (valproate sodium)
    +
    magnesium citrate
    1 interaction

    Caution Advised

    valproic acid + magnesium citrate

    caution advised if valproic acid seizure disorder use and magnesium citrate bowel prep use: combo may alter seizure control (antagonistic effects, magnesium citrate may decr. seizure threshold)

  • meclizine
  • Depacon (valproate sodium)
    +
    meclizine
    1 interaction

    Caution Advised

    valproic acid + meclizine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • mefloquine
  • Depacon (valproate sodium)
    +
    mefloquine
    1 interaction

    Caution Advised

    valproic acid + mefloquine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, mefloquine may decr. seizure threshold)

  • melatonin
  • Depacon (valproate sodium)
    +
    melatonin
    1 interaction

    Caution Advised

    valproic acid + melatonin

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, melatonin may decr. seizure threshold)

  • meprobamate
  • Depacon (valproate sodium)
    +
    meprobamate
    1 interaction

    Caution Advised

    valproic acid + meprobamate

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • methamphetamine
  • Depacon (valproate sodium)
    +
    methamphetamine
    1 interaction

    Caution Advised

    valproic acid + methamphetamine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, methamphetamine may decr. seizure threshold)

  • methocarbamol
  • Depacon (valproate sodium)
    +
    methocarbamol
    1 interaction

    Caution Advised

    valproic acid + methocarbamol

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, methocarbamol may decr. seizure threshold)

  • methoxy polyethylene glycol-epoetin beta
  • Depacon (valproate sodium)
    +
    methoxy polyethylene glycol-epoetin beta
    1 interaction

    Caution Advised

    valproic acid + methoxy polyethylene glycol-epoetin beta

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, methoxy polyethylene glycol-epoetin beta may decr. seizure threshold)

  • methsuximide
  • Depacon (valproate sodium)
    +
    methsuximide
    1 interaction

    Caution Advised

    valproic acid + methsuximide

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • methyldopa
  • Depacon (valproate sodium)
    +
    methyldopa
    1 interaction

    Caution Advised

    valproic acid + methyldopa

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • metronidazole
  • Depacon (valproate sodium)
    +
    metronidazole
    1 interaction

    Caution Advised

    valproic acid + metronidazole

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, metronidazole may decr. seizure threshold)

  • metyrapone
  • Depacon (valproate sodium)
    +
    metyrapone
    1 interaction

    Caution Advised

    valproic acid + metyrapone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • metyrosine
  • Depacon (valproate sodium)
    +
    metyrosine
    1 interaction

    Caution Advised

    valproic acid + metyrosine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • mexiletine
  • Depacon (valproate sodium)
    +
    mexiletine
    1 interaction

    Caution Advised

    valproic acid + mexiletine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, mexiletine may decr. seizure threshold)

  • milsaperidone
  • Depacon (valproate sodium)
    +
    milsaperidone
    1 interaction

    Caution Advised

    valproic acid + milsaperidone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, milsaperidone may lower seizure threshold)

  • molindone
  • Depacon (valproate sodium)
    +
    molindone
    1 interaction

    Caution Advised

    valproic acid + molindone

    caution advised: combo may alter seizure control; may incr. risk of CNS depression, psychomotor impairment (antagonistic effects, molindone may decr. seizure threshold; additive effects)

  • moxifloxacin
  • Depacon (valproate sodium)
    +
    moxifloxacin
    1 interaction

    Caution Advised

    valproic acid + moxifloxacin

    caution advised: combo may decr. moxifloxacin levels, efficacy; may alter seizure control (UGT induced; antagonistic effects, moxifloxacin may decr. seizure threshold)

  • nafarelin nasal
  • Depacon (valproate sodium)
    +
    nafarelin nasal
    1 interaction

    Caution Advised

    valproic acid + nafarelin nasal

    caution advised: combo may incr. risk of bone loss; may alter seizure control (additive effects; antagonistic effects, nafarelin may decr. seizure threshold)

  • nafcillin
  • Depacon (valproate sodium)
    +
    nafcillin
    1 interaction

    Caution Advised

    valproic acid + nafcillin

    caution advised if seizure disorder use, especially w/ high nafcillin doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, nafcillin may decr. seizure threshold)

  • naltrexone
  • Depacon (valproate sodium)
    +
    naltrexone
    1 interaction

    Caution Advised

    valproic acid + naltrexone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • naratriptan
  • Depacon (valproate sodium)
    +
    naratriptan
    1 interaction

    Caution Advised

    valproic acid + naratriptan

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • nefazodone
  • Depacon (valproate sodium)
    +
    nefazodone
    1 interaction

    Caution Advised

    valproic acid + nefazodone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, nefazodone may decr. seizure threshold)

  • ofloxacin
  • Depacon (valproate sodium)
    +
    ofloxacin
    1 interaction

    Caution Advised

    valproic acid + ofloxacin

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, ofloxacin may decr. seizure threshold)

  • orphenadrine
  • Depacon (valproate sodium)
    +
    orphenadrine
    1 interaction

    Caution Advised

    valproic acid + orphenadrine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • oxacillin
  • Depacon (valproate sodium)
    +
    oxacillin
    1 interaction

    Caution Advised

    valproic acid + oxacillin

    caution advised if seizure disorder use, especially w/ high oxacillin doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, oxacillin may decr. seizure threshold)

  • oxcarbazepine
  • Depacon (valproate sodium)
    +
    oxcarbazepine
    1 interaction

    Caution Advised

    valproic acid + oxcarbazepine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • paliperidone
  • Depacon (valproate sodium)
    +
    paliperidone
    1 interaction

    Caution Advised

    valproic acid + paliperidone

    caution advised: combo may incr. paliperidone levels, risk of CNS depression, psychomotor impairment, other adverse effects; may alter seizure control (hepatic metabolism possibly inhibited, additive effects; antagonistic effects, paliperidone may decr. seizure threshold)

  • passion flower
  • Depacon (valproate sodium)
    +
    passion flower
    1 interaction

    Caution Advised

    valproic acid + passion flower

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • penicillin V
  • Depacon (valproate sodium)
    +
    penicillin V
    1 interaction

    Caution Advised

    valproic acid + penicillin V

    caution advised if seizure disorder use, especially w/ high penicillin V doses or concomitant renal impairment: combo may alter seizure control (antagonistic effects, penicillin V may decr. seizure threshold)

  • perampanel
  • Depacon (valproate sodium)
    +
    perampanel
    1 interaction

    Caution Advised

    valproic acid + perampanel

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • phendimetrazine
  • Depacon (valproate sodium)
    +
    phendimetrazine
    1 interaction

    Caution Advised

    valproic acid + phendimetrazine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, phendimetrazine may decr. seizure threshold)

  • pheniramine
  • Depacon (valproate sodium)
    +
    pheniramine
    1 interaction

    Caution Advised

    valproic acid + pheniramine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • phentermine
  • Depacon (valproate sodium)
    +
    phentermine
    1 interaction

    Caution Advised

    valproic acid + phentermine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, phentermine may decr. seizure threshold)

  • pimozide
  • Depacon (valproate sodium)
    +
    pimozide
    1 interaction

    Caution Advised

    valproic acid + pimozide

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, pimozide may decr. seizure threshold)

  • polyethylene glycol
  • Depacon (valproate sodium)
    +
    polyethylene glycol
    1 interaction

    Caution Advised

    valproic acid + polyethylene glycol

    caution advised if valproic acid seizure disorder use and polyethylene glycol bowel prep use: combo may alter seizure control (antagonistic effects, polyethylene glycol may decr. seizure threshold)

  • polyethylene glycol/electrolytes
  • Depacon (valproate sodium)
    +
    polyethylene glycol/ electrolytes
    1 interaction

    Caution Advised

    valproic acid + polyethylene glycol/ electrolytes

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, polyethylene glycol/electrolytes may decr. seizure threshold)

  • pramipexole
  • Depacon (valproate sodium)
    +
    pramipexole
    1 interaction

    Caution Advised

    valproic acid + pramipexole

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • prochlorperazine
  • Depacon (valproate sodium)
    +
    prochlorperazine
    1 interaction

    Caution Advised

    valproic acid + prochlorperazine

    caution advised if seizure disorder use: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, prochlorperazine may decr. seizure threshold)

  • protriptyline
  • Depacon (valproate sodium)
    +
    protriptyline
    1 interaction

    Caution Advised

    valproic acid + protriptyline

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, protriptyline may decr. seizure threshold)

  • pyridostigmine
  • Depacon (valproate sodium)
    +
    pyridostigmine
    1 interaction

    Caution Advised

    valproic acid + pyridostigmine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, pyridostigmine may decr. seizure threshold)

  • pyrilamine
  • Depacon (valproate sodium)
    +
    pyrilamine
    1 interaction

    Caution Advised

    valproic acid + pyrilamine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • quetiapine
  • Depacon (valproate sodium)
    +
    quetiapine
    1 interaction

    Caution Advised

    valproic acid + quetiapine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, quetiapine may decr. seizure threshold)

  • quinine
  • Depacon (valproate sodium)
    +
    quinine
    1 interaction

    Caution Advised

    valproic acid + quinine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, quinine may decr. seizure threshold)

  • raltegravir
  • Depacon (valproate sodium)
    +
    raltegravir
    1 interaction

    Caution Advised

    valproic acid + raltegravir

    caution advised: combo may decr. raltegravir levels, efficacy (UGT induced)

  • ramelteon
  • Depacon (valproate sodium)
    +
    ramelteon
    1 interaction

    Caution Advised

    valproic acid + ramelteon

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • rasagiline
  • Depacon (valproate sodium)
    +
    rasagiline
    1 interaction

    Caution Advised

    valproic acid + rasagiline

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • regadenoson
  • Depacon (valproate sodium)
    +
    regadenoson
    1 interaction

    Caution Advised

    valproic acid + regadenoson

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, regadenoson may decr. seizure threshold)

  • repotrectinib
  • Depacon (valproate sodium)
    +
    repotrectinib
    1 interaction

    Caution Advised

    valproic acid + repotrectinib

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • risperidone
  • Depacon (valproate sodium)
    +
    risperidone
    1 interaction

    Caution Advised

    valproic acid + risperidone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, risperidone may decr. seizure threshold)

  • rivastigmine
  • Depacon (valproate sodium)
    +
    rivastigmine
    1 interaction

    Caution Advised

    valproic acid + rivastigmine

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, rivastigmine may decr. seizure threshold)

  • rizatriptan
  • Depacon (valproate sodium)
    +
    rizatriptan
    1 interaction

    Caution Advised

    valproic acid + rizatriptan

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • roflumilast
  • Depacon (valproate sodium)
    +
    roflumilast
    1 interaction

    Caution Advised

    valproic acid + roflumilast

    caution advised: combo may decr. roflumilast levels, efficacy (hepatic metabolism induced)

  • ropinirole
  • Depacon (valproate sodium)
    +
    ropinirole
    1 interaction

    Caution Advised

    valproic acid + ropinirole

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • rotigotine transdermal
  • Depacon (valproate sodium)
    +
    rotigotine transdermal
    1 interaction

    Caution Advised

    valproic acid + rotigotine transdermal

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • safinamide
  • Depacon (valproate sodium)
    +
    safinamide
    1 interaction

    Caution Advised

    valproic acid + safinamide

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • selegiline
  • Depacon (valproate sodium)
    +
    selegiline
    1 interaction

    Caution Advised

    valproic acid + selegiline

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • selegiline transdermal
  • Depacon (valproate sodium)
    +
    selegiline transdermal
    1 interaction

    Caution Advised

    valproic acid + selegiline transdermal

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, selegiline may decr. seizure threshold)

  • silodosin
  • Depacon (valproate sodium)
    +
    silodosin
    1 interaction

    Caution Advised

    valproic acid + silodosin

    caution advised: combo may incr. silodosin levels, risk of adverse effects (UGT possibly inhibited)

  • sodium picosulfate
  • Depacon (valproate sodium)
    +
    sodium picosulfate
    1 interaction

    Caution Advised

    valproic acid + sodium picosulfate

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, sodium picosulfate may decr. seizure threshold)

  • solifenacin
  • Depacon (valproate sodium)
    +
    solifenacin
    1 interaction

    Caution Advised

    valproic acid + solifenacin

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • sulfate bowel prep
  • Depacon (valproate sodium)
    +
    sulfate bowel prep
    1 interaction

    Caution Advised

    valproic acid + sulfate bowel prep

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, sulfate bowel prep may decr. seizure threshold)

  • sumatriptan
  • Depacon (valproate sodium)
    +
    sumatriptan
    1 interaction

    Caution Advised

    valproic acid + sumatriptan

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, sumatriptan may decr. seizure threshold)

  • tacrolimus
  • Depacon (valproate sodium)
    +
    tacrolimus
    1 interaction

    Caution Advised

    valproic acid + tacrolimus

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, tacrolimus may decr. seizure threshold)

  • tasimelteon
  • Depacon (valproate sodium)
    +
    tasimelteon
    1 interaction

    Caution Advised

    valproic acid + tasimelteon

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • terbutaline
  • Depacon (valproate sodium)
    +
    terbutaline
    1 interaction

    Caution Advised

    valproic acid + terbutaline

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, terbutaline may decr. seizure threshold)

  • tetrabenazine
  • Depacon (valproate sodium)
    +
    tetrabenazine
    1 interaction

    Caution Advised

    valproic acid + tetrabenazine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • tiagabine
  • Depacon (valproate sodium)
    +
    tiagabine
    1 interaction

    Caution Advised

    valproic acid + tiagabine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • tinidazole
  • Depacon (valproate sodium)
    +
    tinidazole
    1 interaction

    Caution Advised

    valproic acid + tinidazole

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, tinidazole may decr. seizure threshold)

  • tizanidine
  • Depacon (valproate sodium)
    +
    tizanidine
    1 interaction

    Caution Advised

    valproic acid + tizanidine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • tolcapone
  • Depacon (valproate sodium)
    +
    tolcapone
    1 interaction

    Caution Advised

    valproic acid + tolcapone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • tolterodine
  • Depacon (valproate sodium)
    +
    tolterodine
    1 interaction

    Caution Advised

    valproic acid + tolterodine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • tranexamic acid
  • Depacon (valproate sodium)
    +
    tranexamic acid
    1 interaction

    Caution Advised

    valproic acid + tranexamic acid

    if seizure disorder use, caution advised w/ high-dose IV tranexamic acid: combo may alter seizure control (antagonistic effects, tranexamic acid may decr. seizure threshold)

  • triamcinolone
  • Depacon (valproate sodium)
    +
    triamcinolone
    1 interaction

    Caution Advised

    valproic acid + triamcinolone

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, triamcinolone may decr. seizure threshold)

  • trifluoperazine
  • Depacon (valproate sodium)
    +
    trifluoperazine
    1 interaction

    Caution Advised

    valproic acid + trifluoperazine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, trifluoperazine may decr. seizure threshold)

  • trihexyphenidyl
  • Depacon (valproate sodium)
    +
    trihexyphenidyl
    1 interaction

    Caution Advised

    valproic acid + trihexyphenidyl

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • trimipramine
  • Depacon (valproate sodium)
    +
    trimipramine
    1 interaction

    Caution Advised

    valproic acid + trimipramine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, trimipramine may decr. seizure threshold)

  • triprolidine
  • Depacon (valproate sodium)
    +
    triprolidine
    1 interaction

    Caution Advised

    valproic acid + triprolidine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • triptorelin
  • Depacon (valproate sodium)
    +
    triptorelin
    1 interaction

    Caution Advised

    valproic acid + triptorelin

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, triptorelin may decr. seizure threshold)

  • trospium
  • Depacon (valproate sodium)
    +
    trospium
    1 interaction

    Caution Advised

    valproic acid + trospium

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • valacyclovir
  • Depacon (valproate sodium)
    +
    valacyclovir
    1 interaction

    Caution Advised

    valproic acid + valacyclovir

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, acyclovir may decr. seizure threshold)

  • valbenazine
  • Depacon (valproate sodium)
    +
    valbenazine
    1 interaction

    Caution Advised

    valproic acid + valbenazine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • valerian
  • Depacon (valproate sodium)
    +
    valerian
    1 interaction

    Caution Advised

    valproic acid + valerian

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • varenicline
  • Depacon (valproate sodium)
    +
    varenicline
    1 interaction

    Caution Advised

    valproic acid + varenicline

    caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, varenicline may decr. seizure threshold)

  • vigabatrin
  • Depacon (valproate sodium)
    +
    vigabatrin
    1 interaction

    Caution Advised

    valproic acid + vigabatrin

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • viloxazine
  • Depacon (valproate sodium)
    +
    viloxazine
    1 interaction

    Caution Advised

    valproic acid + viloxazine

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • vorasidenib
  • Depacon (valproate sodium)
    +
    vorasidenib
    1 interaction

    Caution Advised

    valproic acid + vorasidenib

    caution advised: combo may decr. vorasidenib levels, efficacy (hepatic metabolism induced)

  • ziprasidone
  • Depacon (valproate sodium)
    +
    ziprasidone
    1 interaction

    Caution Advised

    valproic acid + ziprasidone

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment; may alter seizure control (additive effects; antagonistic effects, ziprasidone may decr. seizure threshold)

  • zolmitriptan
  • Depacon (valproate sodium)
    +
    zolmitriptan
    1 interaction

    Caution Advised

    valproic acid + zolmitriptan

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

  • zonisamide
  • Depacon (valproate sodium)
    +
    zonisamide
    1 interaction

    Caution Advised

    valproic acid + zonisamide

    caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@2bdd9be9
  • Brand Discontinued in US

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@5c39001d
  • Brand Discontinued in US

Safety/Monitoring .

Brand Discontinued in US

Look/Sound-Alike Drug Names
Depacon confused with: Decadron

Pregnancy/Lactation .

Pregnancy

Brand Discontinued in US

Lactation

Brand Discontinued in US

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@6266df28

Metabolism: --

Excretion: --

Subclass: Seizure Disorders

Mechanism of Action
--

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: AbbVie Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@3c67d286

DEA/FDA: Discontinued

Retail Price

This information is currently not available for this drug.

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information